Mitochondrial DNA Mutations Induce Mitochondrial Dysfunction, Apoptosis and Sarcopenia in Skeletal Muscle of Mitochondrial DNA Mutator Mice

Asimina Hiona^{1^x}, Alberto Sanz², Gregory C. Kujoth³, Reinald Pamplona⁴, Arnold Y. Seo¹, Tim Hofer¹, Shinichi Someya^{3,5}, Takuya Miyakawa⁵, Chie Nakayama⁵, Alejandro K. Samhan-Arias⁶, Stephane Servais¹, Jamie L. Barger⁷, Manuel Portero-Otín⁴, Masaru Tanokura⁵, Tomas A. Prolla³*, Christiaan Leeuwenburgh¹*

1 Division of Biology of Aging, Department of Aging and Geriatric Research, Institute on Aging, College of Medicine, University of Florida, Gainesville, Florida, United States of America, 2 Mitochondrial Gene Expression and Disease Group. Institute of Medical Technology and Tampere University Hospital, University of Tampere, Tampere, Finland, 3 Department of Genetics and Medical Genetics, University of Wisconsin, Madison, Wisconsin, United States of America, 4 Department of Experimental Medicine, University of Lleida-Institut de Recerca Biomèdica de Lleida, Lleida, Spain, 5 Department of Applied Biological Chemistry, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 6 Department of Biochemistry and Molecular Biology, Faculty of Sciences, University of Extremadura, Badajoz, Spain, 7 LifeGen Technologies, LLC, Madison, Wisconsin, United States of America

Abstract

Background: Aging results in a progressive loss of skeletal muscle, a condition known as sarcopenia. Mitochondrial DNA (mtDNA) mutations accumulate with aging in skeletal muscle and correlate with muscle loss, although no causal relationship has been established.

Methodology/Principal Findings: We investigated the relationship between mtDNA mutations and sarcopenia at the gene expression and biochemical levels using a mouse model that expresses a proofreading-deficient version (D257A) of the mitochondrial DNA Polymerase γ , resulting in increased spontaneous mtDNA mutation rates. Gene expression profiling of D257A mice followed by Parametric Analysis of Gene Set Enrichment (PAGE) indicates that the D257A mutation is associated with a profound downregulation of gene sets associated with mitochondrial function. At the biochemical level, sarcopenia in D257A mice is associated with a marked reduction (35–50%) in the content of electron transport chain (ETC) complexes I, III and IV, all of which are partly encoded by mtDNA. D257A mice display impaired mitochondrial bioenergetics associated with compromised state-3 respiration, lower ATP content and a resulting decrease in mitochondrial membrane potential ($\Delta \psi_m$). Surprisingly, mitochondrial dysfunction was not accompanied by an increase in mitochondrial reactive oxygen species (ROS) production or oxidative damage.

Conclusions/Significance: These findings demonstrate that mutations in mtDNA can be causal in sarcopenia by affecting the assembly of functional ETC complexes, the lack of which provokes a decrease in oxidative phosphorylation, without an increase in oxidative stress, and ultimately, skeletal muscle apoptosis and sarcopenia.

Citation: Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, et al. (2010) Mitochondrial DNA Mutations Induce Mitochondrial Dysfunction, Apoptosis and Sarcopenia in Skeletal Muscle of Mitochondrial DNA Mutator Mice. PLoS ONE 5(7): e11468. doi:10.1371/journal.pone.0011468

Editor: Mark A. Tarnopolsky, McMaster University, Canada

Received February 15, 2010; Accepted May 18, 2010; Published July 7, 2010

Copyright: © 2010 Hiona et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by grants from the National Institute on Aging (AG17994 and AG21042) to CL, National Institutes of Health (AG021905) to TAP, an American Heart Predoctoral Fellowship to AH (0415166B), an American Heart Postdoctoral Fellowship to TH (0525346B), a grant from the Academy of Finland to AS, and an American Heart Predoctoral Fellowship to AYS (0615256B). Oxidative stress analysis was supported by the University of Florida Institute on Aging and Claude D. Pepper Older Americans Independence Center (1 P30 AG028740) Genomics and Biomarker Core. This research was also supported in part by I+D grants from the Spanish Ministry of Education and Science (BFU2006-14495/BFI), the Spanish Ministry of Health (ISCIII, Red de Envejecimiento y Fragilidad, RD06/0013/0012, and Pl081843), and the Autonomous Government of Catalonia (2005SGR00101) to RP and MPO. Additional support was provided to MT by the National Projects on Protein Structural and Functional Analyses from the Ministry of Education, Culture, Sports, Science, and Technologies of Japan. Dr. Barger of LifeGen Technologies was involved with analysis of gene expression data from microarray experiments. No other funders had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: GCK and TAP were awarded United States patent 7,126,040 for the PolgD257A mouse model. TAP is a co-founder and scientific consultant for LifeGen Technologies, specializing in the application of DNA microarray analysis to analyzing nutraceutical interventions in aging. Dr. Barger of LifeGen Technologies was involved with analysis of gene expression data from microarray experiments. This does not alter the authors' adherence to all of the PLoS ONE policies on sharing data and materials.

* E-mail: taprolla@wisc.edu (TAP); cleeuwen@aging.ufl.edu (CL)

¤ Current address: National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, Athens, Greece

Introduction

The progressive loss of skeletal muscle mass and strength observed in older individuals is a condition known as sarcopenia. The associated muscle atrophy and weakness directly affect the functional capacity and quality of life of the elderly. Sarcopenia affects a growing population, occurring in 10-25% of individuals under the age of 70 and in more than 40% of the elderly over the age of 80 [1,2]. The annual cost of treating sarcopenia is greater than the amount spent due to osteoporosis, yet little effort is made to increase public awareness to prevent sarcopenia [3].

Despite the fact that in animal cells mtDNA comprises only 1– 3% of genetic material, several lines of evidence suggest that its contribution to cellular physiology could be much greater than would be expected from its size alone [4,5]. For instance, it mutates at higher rates than nuclear DNA [6,7], which is probably a consequence of: (a) its close proximity to the ETC, and thus of greater exposure to reactants, (b) its lack of protective histones and introns, and (c) its lack of extensive DNA repair systems compared to the nuclear DNA [8,9,10]. Importantly, defects in the ETC can have pleiotropic effects because they affect cellular energetics as a whole [4]. For these reasons, a central role for mitochondrial DNA (mtDNA) mutations in aging has been postulated [11,12,13]. Indeed, mtDNA mutations have been shown to accumulate with aging in several tissues, including skeletal muscle of various species [14,15,16,17,18,19].

Previous studies have provided strong, though correlative, experimental support for an association between mtDNA mutations and tissue dysfunction, particularly in long-lived postmitotic cells such as cardiomyocytes, skeletal muscle fibers and neurons [14,16,17,18,19]. In order to determine whether mtDNA mutations underlie sarcopenia, we used a genetically engineered mouse model that expresses a proofreading-deficient version of the mitochondrial DNA polymerase gamma (D257A), resulting in increased spontaneous mutation rates in mtDNA [20,21]. We have previously characterized accelerated aging in D257A mice [20] and found that these mice exhibited multiple age-related phenotypes including thymic involution, loss of bone mass, cardiac dysfunction and hearing loss. These findings provide support for the hypothesis that mtDNA mutations can play a causal role in mammalian aging [20,21]. Therefore, the D257A mouse may provide an in vivo model to study the mechanisms of skeletal muscle loss with age, specifically, the contribution of mtDNA mutations.

The purpose of the present study was to identify the specific molecular mechanism that links mtDNA mutations and the loss of skeletal muscle mass with age in mitochondrial mutator mice [20]. The central hypothesis tested was that mutations in mitochondrial DNA, known to be associated with aging in many post-mitotic tissues, play a causal role in skeletal muscle loss of mutator mice by affecting the assembly of fully functional ETC complexes, leading to mitochondrial dysfunction and ultimately, to the activation of a mitochondrial-mediated apoptotic program.

Results

D257A mice display significant skeletal muscle loss

At 11-mo of age, D257A mice exhibited significant skeletal muscle loss of gastrocnemius (wild-type, WT: 0.157 ± 0.006 vs. D257A: 0.126 ± 0.006 grams, p=0.0004, -20%) and of quadriceps muscle (WT: 0.190 ± 0.006 vs. D257A: 0.156 ± 0.007 grams, p=0.0003, -18%) compared to WT mice (Fig. 1). The level of sarcopenia is similar to that observed in gastrocnemius of normally-aged (30-mo WT) mice compared to young mice (5-mo WT) (gastrocnemius, 5-mo: 0.146 ± 0.009 vs. 30-mo: 0.110 ± 0.007

grams, p = 0.0095, -24.5%), but less than the level of sarcopenia observed in quadriceps of aged WT mice (5-mo: 0.177 ± 0.004 vs. 30-mo: 0.105 ± 0.007 grams, p = 0.0095, -40%). We next examined whether the observed sarcopenia was due primarily to a reduction in muscle fiber size or fiber number and whether type I or type II fibers were differentially affected. Muscle fiber number and diameter were determined as described [22] for gastrocnemius muscles isolated from 3-mo and 13-mo WT and D257A mice. There were no significant differences between genotypes in the number of type I or type II fibers at either age, although there was a trend toward a lower proportion of type I fibers in the gastrocnemius of D257A mice at both ages (Table 1). By contrast, we observed a significant decrease in the diameter of type I (but not type II) fibers at 13 months of age.

Gene expression profiling of D257A mice

Affymetrix Mouse Genome 430 2.0 arrays were used to measure gene expression profiles in gastrocnemius muscle of 13month old WT and D257A mice. We then performed Parametric Analysis of Gene Set Enrichment (PAGE) [23] to identify classes of genes that were differentially expressed as a result of mtDNA mutations induced by the error-prone mtDNA Polymerase γ . Comparison of 13-month old D257A mice with 13-month old WT mice revealed numerous gene set categories significantly changed in expression (Fig. 2A-C). D257A mice were associated with a dramatic downregulation of "Biological Process" gene sets associated with mitochondrial function, including electron transport chain (GO:0022900), aerobic respiration (GO:0009060), and generation of precursor metabolites and energy (GO:0006091) (Fig. 2A). Downregulation of "Molecular Function" gene sets was also associated with decreased mitochondrial function, including oxidoreductase activity (GO:0016491), NADH dehydrogenase activity (GO:0050662) and cytochrome c oxidase activity (GO:0004129) (Fig. 2B). In the broader "Cellular Component" gene set category, the gene sets mitochondrion (GO:0005739), mitochondrial membrane (GO:0031966) and mitochondrial inner membrane (GO:0005739) were downregulated (Fig. 2C). These observations suggest that there is a transcriptional program to reduce the expression of nuclear-encoded, mitochondrial transcripts in cells that carry functionally impaired mitochondria that result from the accumulation of mtDNA mutations.

Interestingly, gene sets associated with ribosomes or RNA synthesis were the only category of gene sets upregulated in D257A mice. Possibly, impaired bioenergetics in these animals is associated with alterations in protein synthesis and a resulting




Figure 1. D257A mice display significant skeletal muscle loss. At 11 mo of age, gastrocnemius (n=22 per group, *p<0.001) and quadriceps (n=22 per group, *p<0.001) mean muscle mass in D257A mice is significantly decreased compared to age-matched WT. Error bars represent SEM.

doi:10.1371/journal.pone.0011468.g001

Type I Type I Type II Type II Type II Fiber diameter Fiber number Type I Proportion Fiber diameter Fiber number Proportion Genotype (µm, mean ± SEM) (mean ± SEM) (%, mean ± SEM) (µm, mean ± SEM) (mean ± SEM) (%, mean ± SEM) Age 3 mo WT 22.985 ± 0.258 1793±85 27.257 ± 1.330 31.320±0.303 4832±351 72.743±1.330 D257A 22816+0610 1511 ± 128 22659+1427 33072 ± 0980 5144 + 23377 341 + 1 427 3 mo 13 mo WT 25.494±1.368 1533±127 26.584±1.051 31.938±1.373 4203±188 73.416±1.051 13 mo D257A 20.535±0.516* 1612 ± 62 24.792 ± 1.265 28.930±1.525 4929±271 75.208±1.265

Table 1. Fiber type analysis in the gastrocnemius muscle of wild-type and D257A mice.

p<0.01, 13-month WT vs D257A type I fiber diameter comparison. All other comparisons, p>0.05.

doi:10.1371/journal.pone.0011468.t001

attempt to increase protein synthesis through overexpression of ribosomal/translation-related genes. Remarkably, no gene sets associated with apoptosis or DNA damage were induced, suggesting that apoptosis in D257A mice may be an intrinsic mitochondrial process that occurs in the absence of transcriptional induction of classical modulators of mitochondrial apoptosis in response to DNA damage, such as Bak and Bax [24]. This observation is in stark contrast with our previous DNA microarray analysis of skeletal muscle of aged WT animals, which is associated with a marked induction of genes associated with a p53-mediated apoptotic response [25].

At the individual gene expression level, 97 genes were significantly changed in expression in the 13-month old WT vs D257A comparison (p<0.05, FDR <0.05). Mitochondrial Creatine Kinase 2 (*Ckmt2*) was the most significantly altered mitochondrial function transcript (fold change = 1.7, p = 10⁻⁷, FDR = 0.004) (Table S1). Interestingly, comparison between 3-month old WT and 3-month old D257A mice under the same statistical parameters (including same FDR stringency) revealed no significant changes in gene expression either at the individual gene, or PAGE analysis. Thus, changes in gene expression due to the D257A mice, possibly as a consequence of progressive mtDNA mutation accumulation and associated mitochondrial dysfunction.

D257A mice display decreased content and gene expression of ETC Complexes I, III, and IV

We measured the content of ETC complexes I, II, III, IV and the F1 domain of ATPase in 11-mo old WT and D257A skeletal muscle using blue native PAGE (Fig. 3). We found that the total content of complexes I (WT: 40050±2281 vs. D257A: 26100 ± 2724 arbitrary units, p = 0.002, -35%), III (WT: 50970±3673 vs. D257A: 31960±4925 arbitrary units. p = 0.0093, -37%), and IV (WT: 50900 ± 4782 vs. D257A: 25460 ± 5532 arbitrary units, p = 0.0046, -50%), all of which contain subunits encoded by mtDNA, were profoundly reduced in D257A mice (Fig. 3A, 3B). In contrast, the content of complex II (WT: 20710±4079 vs. D257A: 28610±7051 arbitrary units, p = 0.3513) and ATPase F1 (WT: 19760±2831 vs. D257A: 18330 ± 747.9 arbitrary units, p = 0.64), both of which contain only nuclear-encoded subunits, was not different between genotypes (Fig. 3A, 3B). This observation reinforces the idea that the accumulation of mtDNA point mutations directly affects the assembly of complexes that are partly mitochondrial-encoded [26], while strictly nuclear-encoded mitochondrial complexes appear unaffected.

We also measured relative mRNA levels of nuclear encoded genes of the ETC complexes I, III, and IV in 13-mo old WT and D257A skeletal muscle by quantitative RT-PCR (Fig. 4). We

found that the mean relative mRNA expression of *Ndufs1 (complex I)*, *Ndufv1 (complex I)*, *Uqcrc1 (complex III)*, *Cox6a2 (complex IV)*, and *Cox7a1 (complex IV)* in the skeletal muscle of D257A mice was significantly lower than that of WT mice (Fig. 4). These measurements are in agreement with the general finding of reduced expression of gene sets encoding mitochondrial proteins.

ETC complexes specific activities are unaffected in D257A mice

The absolute activities of complexes I and IV (partly mtDNAencoded) appeared to be greatly reduced in the mutant mice (Fig. 5A) whereas for the all-nuclear-encoded complex II, and ATPase F1 domain, we observed no apparent differences between genotypes (Fig. 5A). When we normalized the activity for each sample to the respective respiratory complex content (specific activity), however, we observed no significant differences between WT and D257A mice for all complexes evaluated (Fig. 5B): Complex I (WT: 314.50±13.56 arbitrary units vs. D257A: 349.10 ± 28.80 , p=0.29), complex II (WT: 313 ± 118.90 vs. 163.80 ± 26.30 , p = 0.26), D257A: complex IV (WT: 364.70 ± 19.60 vs. D257A: 440 ± 100.50 , p = 0.49), F1 domain of ATPase (WT: 435.10±96.50 vs. D257A: 384.30±18, p=0.62). We note that large variability in the specific activity in some animal groups (see WT group analysis of complex II activity) may have affected our ability to detect significant changes.

D257A mice show decreased content of both nuclearencoded and mitochondrial-encoded ETC subunits and total mitochondrial protein

In addition to measuring the content of fully assembled and enzymatically active ETC complexes, we further determined the content of selected individual subunits from each complex by Western blotting experiments. We evaluated the subunits NDUFA9 and NDUFS3 from complex I, both of which are nuclear-encoded (Fig. 6A). We also evaluated two nuclear-encoded subunits from complex III, 29 kDa and 48 kDa (Fig. 6A). Lastly, we evaluated the mitochondrial-encoded COX1 subunit from complex IV, which is a part of the active redox center of this complex, and is essential for catalysis (Fig. 6A). We observed a significant down-regulation of protein expression in the D257A mice compared to WT for all subunits evaluated, whether nuclearor mitochondrial-encoded (NDUFA9-WT: 1.47±0.14 arbitrary units vs. D257A: 0.36±0.02, p<0.0001), (NDUFS3-WT: 3.80 ± 0.20 vs. D257A: 3.10 ± 0.20 , p=0.03) (Complex III 48 kDa-WT: 2.05±0.13 vs. D257A: 1.20±0.07, p<0.0001) (COX1-WT: 1.44±0.12 vs. D257A: 0.53±0.05, p<0.0001), with the exception of the 29 kDa subunit of complex III, which only tended to decrease (WT: 0.60±0.06 vs. D257A: 0.47±0.04, p = 0.07) (Fig. 6B).

A. Biological Process

translation
RNA metabolic process
RNA processing
RNA splicing
mRNA metabolic process
mRNA processing
translational initiation
response to biotic stimulus
antigen processing and presentation of peptide antigen
response to bacterium
chemotaxis
taxis
defense response
ribonucleoprotein complex biogenesis
immune response
carboxylic acid catabolic process
organic acid catabolic process
coenzyme metabolic process
mitochondrial ATP synthesis coupled electron transport
oxidative phosphorylation
cofactor metabolic process
ATP synthesis coupled electron transport
respiratory electron transport chain energy derivation by oxidation of organic compounds
cofactor catabolic process
coenzyme catabolic process
oxidation reduction
aerobic respiration
tricarboxylic acid cycle
acetyl-CoA metabolic process
acetyl-CoA catabolic process
cellular respiration
generation of precursor metabolites and energy
electron transport chain

C. Cellular Component

ribonucleoprotein complex ribosome cytosolic ribosome small ribosomal subunit eukaryotic translation initiation factor 3 complex ribosomal subunit nucleolus microbody peroxisome proton-transporting ATP synthase complex proton-transporting ATP synthase complex, coupling factor F mitochondrial membrane part organelle membrane respiratory chain organelle envelope mitochondrial envelope mitochondrial part mitochondrial part mitochondrial inner membrane organelle inner membrane								
<-5	-4	-3	3	4	>5			
		Z-sc	ore					
		D	(GC Er Cy No So No	tron tra 5:00225 hox2 ybb dufa1 dha dufb3 bd2 gcrb		ort cha	in	

Melesular Eurotian в

structural constituent of ribosome mannose binding Sdha RNA binding Ndufb3 RNA binding Uqcrb monosaccharide binding Ndufb9 translation initiation factor activity Ndufb9 translation factor activity, nucleic acid binding Ndufb9 translation factor activity, nucleic acid binding Ndufb9 chemokine receptor binding Ndufb10 oxidoreductase activity, acting on CH-OH group of donors Ndufb10 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufa8 oxidoreductase activity, acting on the CH-OH group of donors Ndufa1 oxidoreductase activity, acting on the CH-OH group of donors Cyc1 oxidoreductase activity, acting on the CH-OH group of donors Cyc1 oxidoreductase activity, acting on the CH-OH group of donors Cyc1 oxidoreductase activity, acting on NADH or NADPH Cyc55 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs8 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs8 NADH dehydrogenase (ubiquinone) activity Ndufs8 Uqcrc1 NADH dehydrogenase (ubiquinone) activity Sdhb Cyb5612 <th colspan="3">B. Molecular Function</th> <th>Ndufa1</th>	B. Molecular Function			Ndufa1
mannose binding Sod2 RNA binding Uqcrb monosaccharide binding Ndufb9 translation initiation factor activity Ndufb9 rRNA binding Ndufb9 translation initiation factor activity, nucleic acid binding Ndufb5 translation factor activity, nucleic acid binding Ndufb1 chemokine activity Ndufb1 chemokine activity, acting on CH-OH group of donors Ndufb1 acyl-CoA dehydrogenase activity Ndufb1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufs1 oxidoreductase activity, acting on the CH-OH group of donors Ndufs1 oxidoreductase activity, acting on the CH-OH group of donors Girx oxidoreductase activity, acting on the CH-OH group of donors Girx oxidoreductase activity, acting on NADH or NADPH Girx oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Oxidoreductase activity oxidoreductase activity Sdhb Ndufs8 NADH dehydrogenase (ubiquinone) activity Tmx4 Cyb56 NADH dehydrogenase activity Tmx4 Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor <th></th> <th></th> <th></th> <th>Sdha</th>				Sdha
RNA binding Uqcrb monosaccharide binding Ndufb9 translation initiation factor activity Ndufb9 rRNA binding Ndufb5 translation factor activity, nucleic acid binding Dld chemokine activity Ndufb10 chemokine receptor binding Uqcrc2 oxidoreductase activity, acting on CH-OH group of donors Ndufb1 oxidoreductase activity, acting on the CH-OH group of donors Ndufv1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Girx oxidoreductase activity, acting on the CH-OH group of donors Ndufv1 oxidoreductase activity, acting on the CH-OH group of donors Sdhb oxidoreductase activity, acting on the CH-OH group of donors Cyc1 oxidoreductase activity, acting on the CH-CH group of donors Cyc1 oxidoreductase activity, acting on NADH or NADPH Cyc1 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs1 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (ubiquinone) activity Cyb5b NADH dehydrogenase (ubi		structural constituent of ribosome		
monosaccharide binding Ndufb9 translation initiation factor activity Ndufb9 rRNA binding Ndufb5 translation factor activity, nucleic acid binding Did chemokine activity Ndufb10 chemokine activity Ndufb3 oxidoreductase activity, acting on CH-OH group of donors Ndufb10 oxidoreductase activity, acting on CH-OH group of donors Ndufb10 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufb1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufb1 oxidoreductase activity, acting on the CH-OH group of donors Ndufb1 oxidoreductase activity, acting on the CH-OH group of donors Cycl oxidoreductase activity, acting on NADH or NADPH Girx oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Girx oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monosalent inorganic cation transmembrane transporter activity Ndufa10 oxidoreductase activity Sdinc NADH dehydrogenase (quinone) activity Sdinc NADH dehydrogenase (quinone) activity Sdinc NADH dehydrogenase activity		mannose binding		
translation initiation factor activity Ndufa9 rRNA binding Ndufb5 translation factor activity, nucleic acid binding Dld chemokine receptor binding Ndufb10 chemokine receptor binding Uqcrc2 oxidoreductase activity, acting on CH-OH group of donors Ndufb10 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufb1 oxidoreductase activity, acting on the Aldehyde or oxo group of donors Ndufb1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on NADH or NADPH Glrx oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 Uqcrc1 NADH dehydrogenase (ubiquinone) activity Sdhb Cyb561d2 Coq7 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Cod7 Cytochorme-c oxidase activity Cod7 vidoreductase activity, acting on heme group of donors, oxy		RNA binding		Uqcrb
rRNA binding Ndufb5 translation factor activity, nucleic acid binding Dld chemokine activity Ndufb10 chemokine receptor binding Uqcrc2 oxidoreductase activity, acting on CH-OH group of donors Ndufb1 acyl-CoA dehydrogenase activity Ndufb1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufs1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufv1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on NADH or NADPH Girx oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyc1 rAD binding Sdhb cofactor binding Ndufs1 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 Uqcrc1 NADH dehydrogenase (ubiquinone) activity Sdhc Tmx4 NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytorchorme-c oxidase activity <td></td> <td>monosaccharide binding</td> <th></th> <td>Ndufb9</td>		monosaccharide binding		Ndufb9
translation factor activity, nucleic acid binding chemokine activity chemokine activity chemokine receptor binding oxidoreductase activity, acting on CH-OH group of donors acyl-CoA dehydrogenase activity oxidoreductase activity, acting on the aldehyde or oxo group of donors oxidoreductase activity, acting on the aldehyde or oxo group of donors oxidoreductase activity, acting on the aldehyde or oxo group of donors oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor oxidoreductase activity, acting on the CH-OH group of donors oxidoreductase activity, acting on NADH or NADPH oxidoreductase activity, acting on the CH-CH group of donors FAD binding cofactor binding cofactor binding oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs1 NADH dehydrogenase (ubiquinone) activity NADH dehydrogenase (ubiquinone) activity NADH dehydrogenase (ubiquinone) activity NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor oxidoreductase activity, acting on heme group of donors, oxygen as acceptor cytochrome-c oxidase activity oxidoreductase activity, acting on heme group of donors, oxygen as acceptor cytochrome-coxidase activity, acting on heme group of donors, oxygen as acceptor cordicate activity, acting on heme group of donors, oxygen as acceptor cordioreductase activity, acting on heme group of donors, oxygen as acceptor cordioreductase activity, acting on heme group of donors coenzyme binding		translation initiation factor activity		Ndufa9
chemokine activity Ndufb10 chemokine activity Uqcrc2 oxidoreductase activity, acting on CH-OH group of donors Ndufs1 acyl-CoA dehydrogenase activity Ndufs1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufs1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on the CH-OH group of donors Girx oxidoreductase activity, acting on the CH-CH group of donors Cyc1 oxidoreductase activity, acting on the CH-CH group of donors Cyc1 oxidoreductase activity, acting on NADH or NADPH Sdhb oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytocrc1 Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytocrc2 Coq7 cytocrc3 Coq7 cytocrc3 Coq7		rRNA binding		Ndufb5
chemokine receptor binding Uqcrc2 oxidoreductase activity, acting on CH-OH group of donors Ndufa8 acyl-CoA dehydrogenase activity Ndufs1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufv1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on NADH or NADPH Glrx oxidoreductase activity, acting on the CH-OH group of donors Cyc1 FAD binding Sdhb cofactor binding Sdhb oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Sdhc NADH dehydrogenase activity Sdhc NADH dehydrogenase activity Sdhc NADH dehydrogenase activity Sdhc NADH dehydrogenase activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity Codase activity oxidoreductase activity, acting on heme group of donors Coq7 cytochrome-c oxidase activity Schc <t< td=""><td></td><td>translation factor activity, nucleic acid binding</td><th></th><td>Dld</td></t<>		translation factor activity, nucleic acid binding		Dld
oxidoreductase activity, acting on CH-OH group of donors Ndufa8 acyl-CoA dehydrogenase activity Ndufs1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufv1 oxidoreductase activity, acting on the CH-OH group of donors Ndufv1 oxidoreductase activity, acting on NADH or NADPH Etfdh oxidoreductase activity, acting on the CH-OH group of donors Cyc1 sidoreductase activity, acting on the CH-CH group of donors Cyc1 oxidoreductase activity, acting on NADH or NADPH Sdhb oxidoreductase activity, acting on NADH or NADPH Sdhb oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyc5b monovalent inorganic cation transmembrane transporter activity Ndufs8 Uqcrc1 NADH dehydrogenase (ubiquinone) activity Sdhc Tmx4 NADH dehydrogenase activity Tmx4 Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 Cots61d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 Cod7 oxidoreductase activity, acting on heme group of donors, coxygen as acceptor Coq7 Cod7 oxidoreductase activity, acting on heme group of donors <t< td=""><td></td><td>chemokine activity</td><th></th><td>Ndufb10</td></t<>		chemokine activity		Ndufb10
acyl-CoA dehydrogenase activity Ndufs1 oxidoreductase activity, acting on the aldehyde or oxo group of donors Ndufs1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on NADH or NADPH Glrx oxidoreductase activity, acting on the CH-CH group of donors Cyc1 FAD binding Sdhb cofactor binding Ndufs1 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufa10 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs8 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufs8 NADH dehydrogenase (ubiquinone) activity Ndufs8 Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc Tmx4 NADH dehydrogenase (quinone) activity Cyb561d2 Coq7 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 Coq7 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 Coq7 oxidoreductase activity, acting on heme group of donors Coq7 Coq7 oxidoreductase activity, acting on heme group of donors Coq7		chemokine receptor binding		Uqcrc2
Los for ContrastNdufv1oxidoreductase activity, acting on the aldehyde or oxo group of donorsNdufv1oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorGlrxoxidoreductase activity, acting on NADH or NADPHGlrxoxidoreductase activity, acting on the CH-CH group of donorsCyc1FAD bindingSdhbcofactor bindingSdhboxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptorNdufa10oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptorNdufs8MADH dehydrogenase (ubiquinone) activityUqcrc1NADH dehydrogenase (ubiquinone) activitySdhcNADH dehydrogenase (quinone) activitySdhcNADH dehydrogenase (quinone) activitySdhcNADH dehydrogenase (quinone) activityCyb561d2oxidoreductase activity, acting on heme group of donors, oxygen as acceptorCoq7cytochrome-c oxidase activityCoq7oxidoreductase activity, acting on heme group of donorsFold changeoxidoreductase activity, acting on heme group of donorsFold change		oxidoreductase activity, acting on CH-OH group of donors		Ndufa8
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor Etfdh oxidoreductase activity, acting on NADH or NADPH Glrx oxidoreductase activity, acting on the CH-CH group of donors Cyc1 FAD binding Sdhb cofactor binding Sdhb oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyc1 monovalent inorganic cation transmembrane transporter activity Ndufa10 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor Tmx4 cytochrome-c oxidase activity Cuptofild oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity oxidoreductase activity, acting on heme group of donors oxidoreductase activity, acting on heme group of donors Coq7 cytochrome-c oxidase activity Scho oxidoreductase activity, acting on heme group of donors Fold change		acyl-CoA dehydrogenase activity		Ndufs1
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor oxidoreductase activity, acting on NADH or NADPH oxidoreductase activity, acting on the CH-CH group of donors FAD binding cofactor binding oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor monovalent inorganic cation transmembrane transporter activity NADH dehydrogenase (ubiquinone) activity NADH dehydrogenase activity NADH dehydrogenase (quinone) activity NADH dehydrogenase (quinone) activity NADH dehydrogenase (quinone) activity NADH dehydrogenase (quinone) activity NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor cytochrome-c oxidase activity neme-copper terminal oxidase activity heme-copper terminal oxidase activity neme group of donors coenzyme bindingEtfdh Glrx Cyb5b NADH Cyb5b Sdhc Tmx4 Cyb561d2 Coq7Fold change		oxidoreductase activity, acting on the aldehyde or oxo group of donors		Ndufv1
oxidoreductase activity, acting on NADH or NADPH GIrx oxidoreductase activity, acting on the CH-CH group of donors Cyc1 FAD binding Sdhb cofactor binding Sdhb oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufa10 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor Cyb561d2 oxidoreductase activity, acting on heme group of donors Coq7 oxidoreductase activity, acting on heme group of donors Coq7 oxidoreductase activity, acting on heme group of donors Fold change		oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor		Etfdh
oxidoreductase activity, acting on the CH-CH group of donors Cyc1 FAD binding Sdhb cofactor binding Ndufa10 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufa10 monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase activity, acting on heme group of donors, oxygen as acceptor Cyb561d2 oxidoreductase activity, acting on heme group of donors Coq7 oxidoreductase activity, acting on heme group of donors Coq7 oxidoreductase activity, acting on heme group of donors Coq7 oxidoreductase activity, acting on heme group of donors Coptotase oxidoreductase activity, acting on heme group of donors Fold change				Glrx
FAD binding Sdhb cofactor binding Ndufa10 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufa10 monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase (quinone) activity Sdhc nydrogen ion transmembrane transporter activity Sdhc oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity Kotidase activity notidoreductase activity, acting on heme group of donors Fold change oxidoreductase activity, acting on heme group of donors Fold change				Cyc1
cofactor binding Ndufa10 oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Ndufa10 monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Ndufs8 NADH dehydrogenase activity Sdhc NADH dehydrogenase (upinone) activity Sdhc NADH dehydrogenase activity Sdhc NADH dehydrogenase activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Cyb561d2 oxidoreductase activity Codase activity heme-copper terminal oxidase activity Codase activity, acting on heme group of donors oxidoreductase activity, acting on heme group of donors Fold change				Sdhb
oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor Cyb5b monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Sdhc NADH dehydrogenase activity Sdhc NADH dehydrogenase (quinone) activity Sdhc NADH dehydrogenase activity Tmx4 Oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Cyb561d2 oxidoreductase activity Copto heme-copper terminal oxidase activity Copto oxidoreductase activity, acting on heme group of donors Fold change				Ndufa10
monovalent inorganic cation transmembrane transporter activity Ndufs8 NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase activity Sdhc NADH dehydrogenase (quinone) activity Tmx4 NADH dehydrogenase (quinone) activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity heme group of donors oxidoreductase activity, acting on heme group of donors Fold change		0		Cyb5b
NADH dehydrogenase (ubiquinone) activity Uqcrc1 NADH dehydrogenase activity Sdhc NADH dehydrogenase activity Tmx4 NADH dehydrogenase (quinone) activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity heme group of donors oxidoreductase activity, acting on heme group of donors Fold change				Ndufs8
NADH dehydrogenase activity Sdhc NADH dehydrogenase (quinone) activity Tmx4 hydrogen ion transmembrane transporter activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity Copper terminal oxidase activity neme-copper terminal oxidase activity Fold change coenzyme binding Fold change		о		Ugcrc1
NADH dehydrogenase (quinone) activity Tmx4 hydrogen ion transmembrane transporter activity Cyb561d2 oxidoreductase activity, acting on heme group of donors, oxygen as acceptor Coq7 cytochrome-c oxidase activity heme-copper terminal oxidase activity oxidoreductase activity, acting on heme group of donors Fold change coenzyme binding Fold change				Sdhc
hydrogen ion transmembrane transporter activity oxidoreductase activity, acting on heme group of donors, oxygen as acceptor cytochrome-c oxidase activity heme-copper terminal oxidase activity oxidoreductase activity, acting on heme group of donors coenzyme binding Fold change				Tmx4
oxidoreductase activity, acting on heme group of donors, oxygen as acceptor cytochrome-c oxidase activity heme-copper terminal oxidase activity oxidoreductase activity, acting on heme group of donors coenzyme binding Fold change				Cyb561d2
cytochrome-c oxidase activity heme-copper terminal oxidase activity oxidoreductase activity, acting on heme group of donors coenzyme binding				Cog7
heme-copper terminal oxidase activity oxidoreductase activity, acting on heme group of donors coenzyme binding Fold change				
oxidoreductase activity, acting on heme group of donors coenzyme binding Fold change				
coenzyme binding Fold change				
				Fold change
			-2x	

Figure 2. Parametric Analysis of Gene Set Enrichment identifies Gene Ontology (GO) terms changed in gastrocnemius muscle of 13month old D257A mice as compared to 13-month old WT mice. (A, B, C) Terms shown are those significantly changed (p<0.01, FDR<0.01). Red indicates a GO term that was induced by mtDNA mutations (Z-score>0); blue indicates GO terms that were suppressed by mtDNA mutations (Zscore<0). n = 5 mice per group. (D) Genes listed within the GO term "electron transport chain" (Z-score = -8.89; p<0.0001) whose expression level significantly (p<0.01) increased (yellow) or decreased (blue) in D257A mice. doi:10.1371/journal.pone.0011468.g002




Figure 3. D257A mice display decreased content of ETC Complexes I, III and IV compared to WT. (A) The total content of ETC complexes I, II, III, IV and the F1 domain of the ATPase from skeletal muscle of 11-mo old WT and D257A mice (n = 7 per group) was determined using Blue Native PAGE electrophoresis followed by staining with commassie blue stain. Proteins were separated according to molecular weight. Representative blots are depicted. (B) Statistical analysis of ETC complexes content. Arbitrary units represent densitometry values normalized to total protein loaded measured by the Bradford assay. Mean values \pm SEM are shown. *p<0.01. doi:10.1371/journal.pone.0011468.q003




Figure 4. D257A mice display decreased mRNA expression of nuclear genes encoding components of ETC Complexes I, III and IV. Relative mRNA expression of genes encoding components of the ETC complexes I, III and IV, including *Ndufs1*, *Ndufv1*, *Uqcrc1*, *Cox6a2*, and *Cox7a1* was measured in the skeletal muscle from WT and D257A mice at 13 months of age by quantative RT-PCR (n = 5 per group). Mean values \pm SEM are shown. *p<0.05. doi:10.1371/journal.pone.0011468.q004

In addition, we compared the mitochondrial protein yield in skeletal muscle of 11-mo and 13-mo old WT mice and D257A mice using a standard Bradford assay. At 11 months of age, we observed a significant reduction (-35%) in mitochondrial protein yield of D257A muscle (WT: 4 ± 0.14 vs. D257A: 2.60 ± 0.06 mg of mitochondrial protein/gram of muscle tissue, p = 0.0044). Additionally, we found that as the mutant mice approach their mean lifespan of ~14-mo, mitochondrial protein yield is even more drastically reduced; by 13-mo of age we detected a 45% decrease compared to WT (WT: 4.30 ± 0.14 vs. D257A: 2.35 ± 0.20 mg of mitochondrial protein/gram of muscle tissue, p < 0.0001), suggesting that mitochondria are progressively eliminated in skeletal muscle of D257A mice.

Mitochondrial bioenergetics is impaired in D257A mice

At 11 months, O_2 consumption during state 4, the resting state of the mitochondria, did not differ between genotypes (WT: 12.70 ± 1.30 vs. D257A:11.90 ±0.95 nmol O_2 /min/mg protein, p=0.31) (Fig. 7A). This was not unexpected because O_2 consumption during this state is usually minimal. During the




Figure 5. No differences between WT and D257A mice in ETC complexes I, II, IV and F1-ATPase specific activity. (A) The activity of ETC complexes I, II, IV and the F1 domain of the ATPase, in skeletal muscle of 11-mo old WT and D257A mice (n = 7 per group), was determined using Blue Native PAGE, followed by enzymatic colorimetric reactions performed on the gels. Representative blots are depicted. (B) Statistical analysis of ETC complexes specific activity. Arbitrary units represent activity densitometry values normalized to respective content densitometry values for each sample. No statistically significant differences were observed. Mean values \pm SEM are shown. doi:10.1371/journal.pone.0011468.q005

phosphorylative state of the mitochondria, state 3 respiration, mutant mitochondria displayed a marked decrease (-43%) in oxygen consumption (WT: 68.40 ± 5.10 vs. D257A: $39\pm$ 5.80 nmol O₂/min/mg protein, p = 0.0006) (Fig. 7A), which also led to a significantly lower respiratory control ratio (RCR: -43%) (Fig. 7A) (WT: 5.70 ± 0.49 vs. D257A: 3.27 ± 0.39 , p = 0.0005). The RCR is used as an index of mitochondrial coupling and metabolic activity. In the case of D257A mitochondria, the significant decrease in RCR with unaltered state 4 respiration denotes a low metabolic activity due to the defects within the ETC complexes (the reduced content) that lead to overall lower oxidative capacity.

D257A mice display decreased ATP content

ATP content was significantly lower in D257A mice compared to WT (WT: 0.29 ± 0.08 vs. D257A: 0.11 ± 0.04 nmol ATP /mg protein, p = 0.046) (Fig. 7B). It is apparent that the loss of ETC complexes (Fig. 3A, 3B) can have an impact on ATP content. Therefore, if ETC content is reduced in D257A muscle relative to the amount of total mitochondrial protein, as we have observed, it is logical to expect that the ATP content per amount of total mitochondrial protein would be reduced due to fewer ETC complexes per mitochondrion. Fewer ETCs cause a decrease in state-3 capacity (Fig. 7A), which may provoke a decrease in phosphorylation.

Mitochondrial membrane potential is significantly lower in D257A mice

We determined the effect of increased mtDNA mutational load on $\Delta \psi_m$ of 13-mo old WT and D257A skeletal muscle mitochondria. $\Delta \psi_m$ was significantly lower in D257A mice during both state 4 (WT: 195.20±1.40 mV vs. D257A: 187.90± 2.15 mV, p=0.017) (Fig. 7C) and state 3 respiration (WT: 177.70±2.50 vs. D257A: 167.30±2.25 mV, p=0.01) (Fig. 7C). This drop in $\Delta \psi_m$ is a consequence of the decreased proton transport that results from the reduction in functional ETC complexes and could be the trigger for the apoptosis we detected in the mutant mice (see below for discussion of apoptosis).

Skeletal muscle mitochondria from D257A mice produce significantly fewer ROS

We measured H₂O₂ produced by skeletal muscle mitochondria of WT and D257A mice. H₂O₂ production was measured during state 4 respiration because ROS production is higher when electron flow is low (ROS production is nearly negligible during state 3 respiration). At 11-mo of age, H₂O₂ production was significantly decreased (-33%) in D257A mice (WT: 0.60±0.07 vs. D257A: 0.40±0.05 nmol H₂O₂/min/mg protein, p=0.01) (Fig. 8A). The decreased H₂O₂ production by mutant mitochondria also led to the calculation of a significantly lower free radical leak percent (FRL%) (WT: 2.60±0.30% vs. D257A: 1.80±0.30%,




Figure 6. D257A mice show decreased protein expression of both nuclear-encoded and mitochondrial-encoded ETC subunits. (A) The content of selected nuclear-encoded (NDUFA9 and NDUFS3 subunits of Cx I, 29 kDa and 48 kDa subunits of Cx III), and mitochondrial-encoded subunits (COX I subunit of Cx IV) in skeletal muscle extracts of 11-mo old WT and D257A mice (n = 11 per group) were evaluated by Western Blotting. Representative blots are depicted. (B) Statistical analysis of ETC subunits protein expression. Arbitrary units represent densitometry values normalized to porin. Mean values \pm SEM are shown. *p<0.05. Cx: complex. doi:10.1371/journal.pone.0011468.g006

p = 0.04) (Fig. 8A), suggesting that in these mitochondria, the fraction of electrons which reduce O_2 to ROS at upstream components of the ETC instead of reaching cytochrome c oxidase (COX) to reduce O_2 to water, is much lower compared to WT.

D257A mitochondria produce fewer ROS in both main ROS generators of the ETC: Complex I and Complex III

We evaluated site-specific ROS generation in 11-mo old mice and found that muscle mitochondria from D257A mice produce fewer ROS at complex III under basal conditions than do WT mitochondria. This is true whether reverse electron flux through complex I is permitted (WT: 6.30 ± 0.47 vs. D257A: 3.13 ± 0.48 nmol H₂O₂/min/mg protein, p=0.0002) (Fig. 8 Bii) or blocked via the complex I inhibitor rotenone (WT: 1.50 ± 0.14 vs. D257A: 0.90 ± 0.12 , p=0.005) (Fig. 8 Biii). Under maximal conditions, D257A mitochondria have also reduced capacity to generate ROS at both complex I (WT: 2.90 ± 0.23 vs. D257A: 1.20 ± 0.19 , p<0.0001) (Fig. 8 Bi) and complex III (WT: 11.90 ± 1.20 vs. D257A: 6.75 ± 0.88 , p=0.003) (Fig. 8 Biv) compared to WT. Moreover, the fact that H₂O₂ production is decreased by nearly a factor of 4 for both WT and D257A mice when the reverse electron flux is blocked (comparing Y axis values from Fig. 8 Bii and Biii) signifies that this reverse flow is a significant source of ROS produced by the ETC.

Mitochondrial DNA mutations cause mitochondrial dysfunction in the absence of increased oxidative stress

In order to correlate our H_2O_2 results with further oxidative stress, we next examined a marker of ROS-induced oxidative damage to DNA, by assessing the levels of 8-oxo-7,8-dihydro-2'deoxyguanosine (8-oxodGuo) in skeletal muscle mtDNA of 11-mo old WT and D257A mice, using HPLC with electrochemical detection. We did not find any differences in the levels of mtDNA oxidation between WT and D257A mice (WT: 51.40±6.30 vs.

mtDNA Mutations & Muscle Loss





Figure 7. Mitochondrial bioenergetics is compromised in D257A skeletal muscle leading to a drop in mitochondrial $\Delta \psi_m$. (A) We determined the effects of mtDNA mutations on O₂ consumption of skeletal muscle mitochondria obtained from 11-mo old WT and D257A mice (n = 11 per group). Oxygen consumption was measured during state 4 (non-phosphorylative state) with pyruvate/malate as substrate, and during state 3 (phosphorylative state) with the addition of ADP. The respiratory control ratio (RCR), an index of mitochondrial coupling and metabolic activity, was calculated by dividing state 3 by state 4 respiration values. Mean values ±SEM are shown. *p<0.001. (B) We evaluated ATP content in skeletal muscle mitochondria of 11-mo old WT (n = 11) and D257A (n = 8) mice using a luciferin-luciferase based bioluminescence assay. Mean values ±SEM are shown. *p<0.05. (C) Changes in $\Delta \psi_m$ were followed qualitatively by monitoring the fluorescence of TMRM that accumulates in energized mitochondria of 13-mo old WT and D257A mice (n = 6 per group). $\Delta \psi_m$ was measured during both state 4 (non-phosphorylative state) with glutamate/malate as substrate and during state 3 (phosphorylative state) with the addition of ADP. Measurement of $\Delta \psi_m$ after addition of CCCP does a control for TMRM loading in mitochondria. Mean values ±SEM are shown. *p<0.02.

D257A: 50.30 ± 7.20 8-oxodGuo/ 10^6 dGuo, p = 0.9) (Fig. 9A). This is consistent with our previous results, which also showed no significant differences between WT and D257A skeletal muscle in

F2-isoprostanes, a marker of lipid peroxidation [20]. Hence, despite increased mutational load, mitochondria from D257A mice do not show increased oxidative stress.



between genotypes

We measured mRNA expression of Catalase and the mitochondrial-specific isoform of superoxide dismutase (SOD), MnSOD, via RT-PCR. We found no difference in either Catalase (WT: 1.20±0.08 vs. D257A: 1.10±0.04 arbitrary units, p = 0.1) (Fig. 9B) or MnSOD (WT: 0.80 ± 0.01 vs. D257A: 0.70 ± 0.07 arbitrary units, p = 0.3 (Fig. 9B) between genotypes.


increase in cytosolic mono- and oligo-nucleosomes content

We quantified apoptotic DNA fragmentation by measuring the amount of mono- and oligo-nucleosomes released into the cytosol, using a quantitative "Cell Death" detection ELISA (Roche, Germany). This assay detects the nucleosomal DNA digestion products of $\sim 180-200$ bp or multiples thereof that are generated during apoptosis. We observed a significant release of these


PLoS ONE | www.plosone.org

15 nmol H₂O₂/min/mg prot


D257A



Succinate **ROS** generation at Complex III + Reverse electron flux



Pyruvate/Malate + Rotenone



2

1

2.0

1.5

1.0

0.5

0.0

nmol H₂O₂/min/mg prot

Biii

ŵτ


ŴТ

Succinate + Rotenone

ROS generation at Complex III


Reverse electron flux blocked

Α



D257A

D257A



10

5

n

ŵт

Biv

Apoptosis in D257A skeletal muscle is evident by an




Figure 9. Mitochondrial DNA oxidation levels and antioxidant enzyme mRNA expression remain unaltered in D257A skeletal muscle. (A) We examined a marker of ROS-induced oxidative damage to DNA by assessing the levels of 8-oxodGuo in skeletal muscle mtDNA of 11-mo old WT and D257A mice (n = 11 per group), using HPLC with electrochemical detection. No statistically significant differences were detected. Mean values \pm SEM are shown. (B) We measured Catalase and MnSOD mRNA expression in skeletal muscle extracts from 11-mo old WT (n = 7) and D257A (n = 8) mice by RT-PCR. Arbitrary units represent specific mRNA densitometry values normalized to actin mRNA densitometry values. No statistically significant differences were detected. Mean values \pm SEM are shown. doi:10.1371/journal.pone.0011468.g009

fragments into the cytosol of D257A muscle (WT: 0.110 ± 0.006 vs. D257A: 0.170 ± 0.030 OD/mg protein, p = 0.035) (Fig. 10A).

DNA laddering is evident in skeletal muscle of D257A mice

We corroborated the results of the cell death ELISA by employing an alternate method for detecting apoptotic nucleosomal DNA fragments, the DNA laddering assay. Prominent DNA ladders are evident in muscle extracts from the D257A mice while such ladders are not observed in WT mice (Fig. 10B).

Caspase-3 and caspase-9 activities are significantly higher in D257A mice

We measured caspase-3 activity in the cytosol of 11-mo old WT and D257A muscle and found that it is significantly higher in the mutant mice (WT: 43 ± 2.70 vs. D257A: 57.70 ± 1.97 RFU/mg protein, p=0.0003) (Fig. 10C). Similarly, caspase-9 activity showed a significant increase in D257A muscle compared to WT muscle (WT: 35.40 ± 2 vs. D257A: 45.30 ± 1.70 RFU/mg protein, p=0.0014) (Fig. 10C). Activation of caspase-9 was significantly correlated with increased caspase-3 activity for both WT (r = 0.97, p<0.0001) and D257A mice (r = 0.80, p = 0.0029) (Fig. 10D). These results reveal the induction of the mitochondrialmediated pathway of apoptosis because activation of the mitochondrial pathway-specific caspase-9 leads to further cleavage and activation of caspase-3, which is directly responsible for the downstream events (*i.e.*, cleavage of endo-nucleases and DNA repair enzymes) that lead to apoptosis.

Discussion

The accumulation of multiple mtDNA point mutations and deletions coincides with the age-dependent loss of muscle fibers in multiple mammalian species [18,27,28,29,30]. Studies on sarcopenia in rodents and humans, using laser capture microdissection show that mtDNA deletions colocalize with ETC dysfunction in specific fiber regions [14,31], with fibers manifesting the phenotype when the ratio of deleted mtDNA genomes is above 80% [31]. Interestingly, mtDNA mutations are absent from phenotypically normal regions within individual muscle fibers




Figure 10. Apoptosis is evident in D257A muscle by increased cytosolic DNA fragments, DNA laddering, and caspase activation. (A) Cytosolic fractions from 11-mo old WT and D257A skeletal muscle (n = 11 per group) were prepared. Nuclear DNA fragmentation was quantified as the amount of mono- and oligo-nucleosomes present in the cytosol, using a sandwich ELISA. Mean values \pm SEM are shown. *p<0.05. OD: optical density. (B) DNA from 13-mo old WT and D257A (n = 8 per group) mice was extracted and subjected to a DNA laddering-specific ligation PCR. PCR products were electrophoresed through 1% agarose gels and visualized under UV light for apoptosis-specific DNA ladders of ~180–200 bp multiples. Lane 1: 100 bp molecular marker. Lanes 2–9: WT PCR products. Lanes 10–17: D257A PCR products. Lane 18: Positive control. Lane 19: 500 bp molecular marker. (C) Cytosolic fractions from 11-mo old WT and D257A skeletal muscle (n = 11 per group) were prepared. Caspase -3 and -9 activities were measured using a fluorometric protease assay kit which is based on detection of cleavage of the substrates DEVD-AFC or LEHD-AFC by caspase-3 and -9 respectively. Mean values \pm SEM are shown. *p<0.002. RFU: raw fluorescent units. (D) Caspase-3 activity was correlated with caspase-9 activity in WT and D257A mice (n = 11 per group). Pearson correlation r values are shown in the top right corner. Correlations were significant for both genotypes; WT: r=0.97, p<0.0001 and D257A: r=0.8, p<0.003. doi:10.1371/journal.pone.0011468.g010

[32]. Similarly, in aged (69–82 years old) human muscle, clonally expanded base-substitution mutations and deletions in mtDNA are associated with a deficiency in the mitochondrially encoded cytochrome c oxidase (COX) [33]. Although ETC deficiency is only observed in fiber regions that cointain high levels of mtDNA deletions, it has been proposed that extension of the ETS-abnormal region eventually extends throughout the length of the fiber leading to fiber athrophy, breakage and loss [31]. Although these studies do not prove causality, they provide evidence in support of the hypothesis that mtDNA mutations and deletions contribute to the development of sarcopenia. The question of correlation versus causality has recently begun to be addressed by

the generation of mitochondrial mutator strains to investigate the role of high mtDNA mutational load on sarcopenia [20]. Here, we extend these observations to characterize in detail the sarcopenic phenotype and mitochondrial respiratory function in skeletal muscle from mutator mice.

Type I and type II muscle fiber numbers were not dramatically different in D257A mice compared to WT control, at least in the gastrocnemius muscle. We did find evidence of muscular atrophy by 13 months in D257A gastrocnemius, represented by an $\sim 20\%$ decrease in type I fiber diameter in these animals. A more dramatic effect of mtDNA mutations accumulation on type I fibers is consistent with the higher mitochondrial density, and reliance on

oxidative phosphorylation in these so-called "slow twitch" fibers relative to classic "fast twitch" type II (particularly type IIb) fibers. Remarkably, the pattern of type I fiber diameter reduction in D257A mice is different than that observed in rodents [34], and humans [35], which are associated with type II fiber atrophy with age. Possibly, the very high load of mtDNA mutations in D257A mice as compared to normally aged WT mice, leads to preferential dysfunction of type I fibers, which rely heavily on oxidative phosphorylation. The difference in fiber type alterations in D257A mice and normal aging could also be interpreted as evidence that mtDNA mutations are not the initiating event in fiber atrophy and sarcopenia in humans. Different mechanisms of muscle aging in D257A and wild-type mice are also supported by the DNA microarray analysis, which is characterized by an extensive induction of p53-induced apoptotic genes in aged wild-type muscle [25], but not in D257A mice as reported here. This may reflect an increased contribution of nuclear genomic instability in normal aging, as compared to aging of D257A mice. However, we also note that the type of mtDNA lesions may play a role in the different observations of D257A mice and normal aging. Importantly, in D257A mice mtDNA point mutations appear to be the predominant lesion [26], whereas mtDNA large deletions are associated with regional fiber dysfunction in humans [31].

We found robust decreases in mitochondrial state 3 (phosphorylative state) O₂ consumption and significantly lower mitochondrial ATP content in gastrocnemius and quadriceps muscles from D257A mice, compared to WT animals. D257A mitochondria were profoundly less metabolically active than controls, as reflected by respiratory control ratios (state 3/state 4 O₂ consumption) of less than 3.5. These findings clearly indicate that oxidative phosphorylation is compromised in skeletal muscle of mutant mice and provide a causal role for mtDNA mutations in skeletal muscle mitochondrial dysfunction. It should be noted that decreases in ATP synthesis and state 3 respiration during normal aging are all welldocumented for multiple species and tissues, including human skeletal muscle [36,37,38,39,40,41]. Our findings in skeletal muscle are also consistent with those of Trifunovic and colleagues, which demonstrated a severe decline in mitochondrial respiration in mouse embryonic fibroblasts and impaired ATP production in the hearts of similar mutator mice [21,26,42].

These defects in oxidative phosphorylation are likely the cause of the drop in mitochondrial membrane potential $(\Delta \psi_m)$ that we have detected in mitochondria from mutant mice. Low $\Delta \psi_{\rm m}$ has also been observed in mitochondria isolated from normally-aged $(\sim 20-30 \text{ mo})$ rodents and from fibroblasts of elderly $(\geq 60 \text{ yr})$ human subjects [43,44,45,46,47], and was found to correlate with reduced ATP synthesis. A reduction in $\Delta \psi_m$ leads to matrix condensation and release of pro-apoptotic factors into the cytosol, facilitating cell death [48]. In our D257A model, the drop in $\Delta \psi_{\rm m}$ was indeed accompanied by up-regulation of apoptosis, as evidenced by an increased release of mono- and oligo-nucleosomal fragments into the cytosol, prominent DNA laddering and upregulation in the activities of caspase-9 and caspase-3. The observation of increased caspase-9 activity as well as the significant positive correlation between caspase-3 and caspase-9 activity in D257A mice suggests that activation of the mitochondrial pathway is at least partly responsible for the apoptosis we detected in D257A muscle. Accelerated skeletal muscle apoptosis has been well documented with aging [49,50] and we previously showed that increased caspase-3 cleavage is characteristic of skeletal muscle during normal aging [20]. Furthermore, previous studies have suggested that age-related apoptosis and/or necrosis in response to energy depletion may occur through activation of the mitochondria-mediated signaling pathway [48,51,52,53].

Accumulation of mtDNA mutations and deletions will likely have a direct impact on the transcription and translation of ETC complexes and may preclude the assembly of functional complexes within the inner mitochondrial membrane. Decreases in the activity of ETC complexes with age, and in association with accumulated mtDNA mutations/deletions, are documented in skeletal muscle of rodents and humans [14,54,55,56,57,58]. Interestingly, D257A mice showed a significant decrease in the content of fully assembled, enzymatically active complexes I, III and IV, all of which contain subunits encoded by mtDNA, while the content of all nuclear-encoded complexes II and F1 domain of ATPase showed no difference between genotypes. This confirms our hypothesis that mtDNA mutations have a direct impact on the assembly of functional ETC complexes that are comprised of mtDNA-encoded subunits. Importantly, when ETC complex specific activity was determined, we did not detect significant differences between genotypes in any of the complex activities, suggesting that either only functional complexes assemble or dysfunctional complexes are effectively degraded. However, this remains to be determined. Nonetheless, even if the activity of the remaining ETC complexes in mutant mitochondria is normal, the reduced amount of functional complexes still creates energy deficits resulting in mitochondrial dysfunction. A point that requires special attention regarding measurements of ETC complex enzymatic activities is how the complex activities are expressed. In most cases, enzymatic activities are normalized to total protein content [37], or expressed as a ratio to nuclearencoded citrate synthase activity [57]. In such cases, the overall activity per amount of mitochondrial protein may not reflect decreases in the actual activity of the individual complexes, but instead decreases in the abundance of the complex [37]. We determined specific activity, as well as complex abundance in order to gain a more precise understanding of the specific defects occurring within D257A mitochondria. Thus, our results show that ETC complexes do not assemble as often in D257A mutant mitochondria. However, those complexes that do manage to assemble have normal activity, perhaps because complexes containing altered proteins might be short-lived.

We also observed a significant down-regulation of mitochondria-related gene sets, and also ETC complex subunits expression in the D257A muscle, whether nuclear- or mitochondrialencoded. The reduced expression of nuclear-encoded subunits may be the consequence of a reactive adaptation of the nucleus. In agreement with this hypothesis, Alemi *et al.* demonstrated that pathogenic mtDNA deletions had a strong negative effect on nuclear-encoded mitochondrially targeted genes [59]. They proposed that the nucleus senses the irreversible depletion of mtDNA-encoded subunits and responds by down-regulating the interacting subunits that would normally form a functional complex. This proposed down-regulation of nuclear-encoded genes related to mitochondria is fully supported by our gene expression findings, and is likely to exacerbate the mitochondrial defect initiated by the mtDNA mutations.

Besides a reduction in the abundance of ETC complexes, we further detected significantly lower mitochondrial protein yield in the mutant mice. Age-related decreases in mitochondrial protein yield in rodent skeletal muscle have been previously reported [60,61], but this finding is not uniform [62]. By 11-mo of age, we detected a 35% reduction and at ~13 months, an even more dramatic 45% reduction in mitochondrial protein yield from D257A muscle, suggesting that mitochondrial content is continuously lost in these animals as they are approaching their mean lifespan of ~14 months. Because we observed decreased ETC complex content and reduced mitochondrial protein yield in

D257A muscle with age, we speculate that this may reflect the selective elimination of dysfunctional, mutation-bearing mitochondria containing the fewest functional ETCs.

The hypothesis that aging is due in part to mtDNA damage and associated mutations [12,13] was based on the observations that mtDNA is located in the organelle that generates the most cellular ROS and it is relatively unprotected from ROS damage compared to nuclear DNA [6,7]. The main tenet of the free radical theory of aging [63] is that aging is due to the progressive accrual of ROSinflicted damage, including mtDNA mutations, the accumulation of which has been postulated to lead to a "vicious cycle" of further mitochondrial ROS generation and mitochondrial dysfunction [12,13]. The increased production of ROS as a consequence of mtDNA mutations has been demonstrated in some circumstances [64,65]. In contrast to these studies, however, we and others have clearly demonstrated that mitochondrial mutator mice do not have increased levels of oxidative stress [20,42,66]. In this study, we further report that in D257A skeletal muscle, mitochondrial ROS production is significantly decreased as compared to WT tissue. Both the basal and maximal ROS production at complex I and at the proton motive Q cycle operating in complex III – the two major ROS sites within the ETC - were significantly lower in mutant skeletal muscle. These results suggest that ROS production is regulated in a tissue-specific way, at least in the D257A model, and does not necessarily play a role in the increased sensitivity to apoptosis. Importantly, we also found no up-regulation in either MnSOD or Catalase mRNA levels, substantiating that ROS levels are decreased in mutant mice due to a lower ROS production and not due to an up-regulation in antioxidant defenses.

In agreement with the ROS data, we found that muscle mtDNA oxidative damage, as measured by 8-oxodGuo, was not different between genotypes. This agrees with our previous 8-oxodGuo data in D257A liver [20] as well as with oxidative stress data reported by others in liver and heart using D257A mutator mice or mice with a heart-specific mitochondrial mutator defect [42,66]. Note that we did not detect a significant change in 8-oxodGuo levels, despite a drop in H₂O₂ production which may implicate non-ETC and extramitochondrial sources of ROS in mtDNA damage [67]. Furthermore, the paired observations of decreased ROS production and a lowered $\Delta \psi_m$ in D257A mice are consistent with the widely accepted notion that increased ROS generation occurs at high mitochondrial $\Delta \psi_m$ s [68,69].

We do not postulate that chronic ROS production and oxidative stress do not contribute to mtDNA damage and mutagenesis in the context of normal aging. In fact, expression of a mitochondrially targeted catalase in wild-type mice suppresses age-related mtDNA mutations and deletions [70,71]. Our results from the D257A model, however, clearly support the idea that in skeletal muscle, mtDNA mutagenesis does not lead to further increases in ROS production and oxidative stress and therefore, these are not important mediators of apoptosis in this animal model. Hence, based on our collective results, we propose instead that respiratory chain dysfunction *per se* is the primary inducer of the sarcopenic phenotype.

We note the observations of Bandy and Davison, the first investigators to put forward a mechanistic elaboration of the mitochondrial "vicious cycle" theory. While they showed that some mtDNA mutations may stimulate ROS production, they also carefully noted that mutations preventing the synthesis of cytochrome b would actually abolish any superoxide production at complex III that normal mitochondria might exhibit, because without cytochrome b in place, complex III cannot be assembled [72]. Later studies also reported that cells possessing large mtDNA deletions would indisputably preclude assembly of both the enzyme complexes known to be responsible for mitochondrial ROS production, complexes I and III [27,73,74,75]. Our findings of lower complex I and III content in combination with lower complex I and III ROS production are in agreement with those studies.

We note that there is debate on the contributing role of point mutations as opposed to deletions in the manifestation of the premature aging phenotypes in mitochondrial mutator mice. Interestingly, heterozygous D257A animals are able to sustain a 500-fold higher mtDNA mutation burden than WT mice without any obvious features of rapidly accelerated aging, indicating that mtDNA point mutations do not limit the natural lifespan of WT mice [70]. We have previously shown that mtDNA deletions accumulate at an accelerated rate in tissues of homozygous D257A (the mice used in this study), and postulated that they may represent the main driving force behind the shortened lifespan and the various aging phenotypes in these mice [71]. Moreover, clonally expanded mutations were also evident in D257A mice as demonstrated by cells with a COX negative phenotype in various tissues investigated [71]. However, a recent study reports no major reductions in the levels of mitochondrially encoded transcripts in D257A mice, suggesting that large numbers of point mutations (as opposed to deletions) underlie the phenotypes of D257A mice [26]. In our view, it is likely that both mtDNA deletions and point mutations contribute to the phenotypes observed in homozygous D257A mice, but that these lesions may have different abundance and consequences in different tissues.

The D257A mice are the first "in vivo" mammalian system that allows detailed examination of the causal role of mtDNA mutations in skeletal muscle aging. We observed no differences between genotypes in muscle mass [20], caspase-3 cleavage [20], gene expression patterns, mitochondrial bioenergetics (Fig. S1) and ROS production (Fig. S2) at an early age (3-mo), suggesting that the sarcopenic phenotype in D257A mice is age-induced and not due to developmental defects, underscoring the utility of D257A mice as a model of age-related mitochondrial dysfunction. We propose that the reduction in functional complexes I, III and IV formation in D257A mice represents the primary mechanism responsible for impaired mitochondrial bioenergetics (limited oxidation and phosphorylation capacities). Ultimately, lower electron transfer and decreased proton pumping lead to disturbances in $\Delta \psi_{\rm m}$ and mitochondrial-mediated apoptosis. Importantly, this work is also the first to demonstrate specifically in skeletal muscle, that mtDNA mutations lead to mitochondrial dysfunction concurrent with decreases in ROS production, in contrast to the mitochondrial "vicious cycle" theory of aging. This reduction in ROS is possibly due to: (a) the drop in $\Delta \psi_{\rm m}$, and (b) the less frequent formation of the main ROS generators, complexes I and III. Our findings suggest that accumulation of mtDNA mutations and associated respiratory dysfunction may lead to the activation of apoptosis and loss of irreplaceable cells in susceptible tissues, and therefore may be an important contributor to the aging process.

We note that the D257A model does not represent the multiple aspects of normal skeletal muscle aging, but is a model that addresses the role of mtDNA mutations in age-related mitochondrial dysfunction. Although mtDNA deletions were found to accumulate significantly in tissues of WT mice with age, they accumulate at a 7–11 fold higher level in tissues of D257A mice [70], while point mutations can reach ~2,500-fold higher occurrence compared to WT mice [71]. Moreover, because cells may have hundreds of mitochondria, and each carries multiple copies of mtDNA likely coexisting as heteroplasmic mtDNA sequences, the contribution of mtDNA mutations and deletions to normal aging phenotypes remains a controversial issue.

Materials and Methods

Generation of D257A mice

The generation of $Polg^{D257A}$ transgenic mice has been previously reported [20]. Briefly, the D257A mutation results in a critical residue substitution in the conserved exonuclease domain of POLG, impairing its proofreading ability. Germline transmission of the mutation produced $Polg^{+/D257A}$ mice, which were intercrossed to generate homozygous $Polg^{D257A/D257A}$ mice, hereafter denoted D257A.

Animals

All animal research was conducted in accordance with the regulatory policies of the Institutional Animal Care and Use Committees of the University of Florida (CL approved protocol #D420) and the University of Wisconsin-Madison (TAP approved protocol #M01265). Male and female WT and D257A mice (initially of a mixed 129Sv/ICR/B6 background before being backcrossed for 4 generations into a C57Bl/6J background) were sacrificed at 11 and 13 months of age, timepoints at which the D257A mice exhibit age-related muscle loss; indeed, muscle loss may be evident as early as ~ 9 months of age in these mice [20]. Males and females were pooled for statistical analysis based on our previous observation that there are no differences between sexes in the parameters studied in WT mice of the same background [76]. The animals were housed in guarantines in a climate- and lightcontrolled facility. After one week of acclimation in the facility the animals were sacrificed by rapid cervical dislocation. Four animals a day were sacrificed. For all of our experiments we used and compared two groups: WT versus D257A mice. For some experiments, 3 mo-old WT and D257A mice were also used (refer to Fig. S1 and S2). Five-mo (n = 15) and 30-mo old (n = 10)WT animals of the same background strain were also used for muscle weight comparisons.

Measurements of number and diameter of muscle fiber. Type I and II fibers were discerned with NADH-tetrazolium reductase stain. Detailed protocols for the stain have been described [22]. The number and diameter of each type fiber were measured in the microscopic images of transverse sections of the gastrocnemius muscles. The diameter was calculated by Image J (NIH) and the data sets from >150 type I fibers and >200 type II fibers were analyzed by ANOVA with Bonferroni's multiple comparison test.

Mitochondrial and cytosolic isolation

Mitochondrial and cytosolic protein fractions were isolated using differential centrifugation as previously described [76]. Immediately after sacrifice, skeletal muscles from 11-mo old WT and D257A mice (both gastrocnemius and quadriceps muscles were pooled together for all of our biochemical analyses) were extracted, rinsed in saline solution, weighted, then finely minced and homogenized in (1:5 wt/vol) ice-cold isolation buffer containing 0.21 M mannitol, 0.07 M sucrose, 0.005 M Hepes, 0.001 M EDTA, 0.2% fatty acid-free BSA, pH 7.4, using a Potter-Elvehjem glass homogenizer. The homogenate was centrifuged at $1,000 \times g$ for 10 min at 4°C. The supernatant was then centrifuged at 14,000 \times g for 20 min. After the second spin, the supernatant (crude cytosol) was stored at -80° C and the mitochondrial pellet was resuspended in isolation buffer without BSA and was centrifuged again at 14,000 \times g for 10 min. The final mitochondrial pellet was resuspended in 350 μ l of isolation buffer without BSA.

Total basal and site-specific ROS production

The rate of mitochondrial H_2O_2 production was assayed in freshly isolated mitochondria by a highly sensitive fluorometric

method according to Barja [77], and adapted to a microplate reader [76]. H₂O₂ generation was monitored by measuring the increase in fluorescence (excitation at 312 nm, emission at 420 nm) due to the oxidation of homovanillic acid by H2O2 in the presence of horseradish peroxidase. The assay was performed in incubation buffer (145 mM KCl, 30 mM Hepes, 5 mM KH₂PO₄, 3 mM MgCl₂, 0.1 mM EGTA, 0.1% BSA, pH 7.4) at 37°C, and the reaction conditions were: 0.25 mg of mitochondrial protein per mL, 6 U/mL of horseradish peroxidase, 0.1 mM homovanillic acid and 50 U/mL of superoxide dismutase (SOD). The reaction was initiated by the addition of 2.5 mM pyruvate/ 2.5 mM malate as substrate for oxidative phosphorylation. Pyruvate/malate was used to study complex I ROS production which also represents total basal mitochondrial ROS generation. 5 mM succinate without addition of inhibitors was used to study complex III ROS production, under near physiological conditions, as previously described [76,77]. We also used inhibitors of the ETC in order to study maximum rates of H₂O₂ production from complexes I and III, since they represent the main sites of ROS generation within the mitochondria. For the determination of maximal H_2O_2 production by complex I, 2 μ M rotenone was added to 2.5 mM pyruvate/2.5 mM malate-supplemented mitochondria. For the determination of maximal H₂O₂ production by complex III, 2 µM antimycin A plus 2 µM rotenone were added to succinate-supplemented mitochondria. In addition, some of the assays in which succinate was used as the substrate were performed in the presence of 2 μ M rotenone alone, in order to avoid the "backward" flow of electrons to Complex I. After 15 min of incubation at 37°C, the reaction was stopped and the samples were transferred on ice and a stop solution (0.1 M glycine, 25 mM EDTA, pH 12) was added. Known amounts of H₂O₂ generated in parallel by glucose oxidase, with glucose as substrate, were used as standards. All samples were run in duplicate.

Mitochondrial respiration

Mitochondrial oxygen consumption was measured at 37° C by polarography, with a Clark-type oxygen electrode (Oxytherm, Hansatech, Norfolk, UK) under the same conditions used (same mitochondrial preparation, buffer composition and substrate concentrations) for H₂O₂ production measurements. The assay was performed in the absence (State 4-resting state) and in the presence (State 3-phosphorylating state) of 500 μ M ADP.

ATP content

Mitochondria isolated from skeletal muscle were used immediately after isolation to determine mitochondrial ATP content with a luciferin-luciferase based bioluminescence assay, following the method of Drew [78]. ATP content methodology was modified from a method of Molecular Probes (A-22066, Eugene, OR, USA). The chemicals used were D-luciferin, luciferase (40 μ L of a 5 mg/mL solution in 25 mM Tris-acetase, pH 7.8, 0.2 M ammonium sulfate, 15% (v/v) glycerol and 30% (v/v) ethylene glycol), dithiothreitol (DTT), adenosine 5'-triphosphate (ATP), and a Reaction Buffer (10 mL of 500 mM Tricine buffer, pH 7.8, 100 mM MgSO₄, 2 mM EDTA and 2 mM sodium azide). The reagents and reaction mixture were combined according to the protocol by Molecular Probes. In order to determine ATP content, freshly isolated mitochondria were added to a cuvette containing reaction buffer, D-luciferin, luciferase and DTT. In addition, 2.5 mM pyruvate and 2.5 mM malate were added to the reaction mixture, as substrates for oxidative phosphorylation. Known concentrations of ATP standards were used to establish a standard curve. The values for ATP content were normalized to total mitochondrial protein concentration.

Mitochondrial membrane potential

 $\Delta \psi_{\rm m}$ changes in isolated skeletal muscle mitochondria were followed qualitatively by monitoring the fluorescence of tetramethyl rhodamine methyl ester (TMRM, Molecular Probes, Eugene, OR, USA), a cationic lipid-soluble probe that accumulates in energized mitochondria. The method of Scaduto [79] was followed without modification. Briefly, mitochondria (0.25 mg/ml) were incubated at 37°C in a medium composed of 135 mM KCl, 20 mM MOPS, 5 mM K₂HPO₄, and 5 mM MgCl₂ at pH 7.00. The experiment was initiated by the addition of mitochondria to the medium, also containing 0.33 mM TMRM and 5 mM glutamate +2.5 mM malate in order to record $\Delta \psi_{\rm m}$ during state 4. Fluorescence at 546 and 573 nm excitation was monitored using an emission wavelength of 590 nm. This was followed by the addition of ADP (0.17 mM) to record $\Delta \psi_{\rm m}$ during state 3. Addition of 0.5 mM CCCP served as a positive control, to assess $\Delta \psi_{\rm m}$ in completely depolarized mitochondria.

Calculation of the mitochondrial free radical leak

 H_2O_2 production and O_2 consumption were measured in parallel in the same muscle mitochondria under similar experimental conditions. This allowed the calculation of the fraction of electrons which reduce O_2 to ROS at upstream components of the respiratory chain (the percent free radical leak or FRL%) instead of reaching cytochrome oxidase to reduce O_2 to water. Because two electrons are needed to reduce 1 mole of O_2 to H_2O_2 whereas four electrons are transferred in the reduction of 1 mole of O_2 to water, the percent free radical leak can be calculated as the rate of H_2O_2 production divided by two times the rate of O_2 consumption, and the result is multiplied by 100.

Calculation of the mitochondrial respiratory control ratio (RCR)

Measurement of oxygen consumption using a Clark-type electrode in the absence (State 4) and presence (State 3) of saturating amounts of ADP (500 μ M) allowed calculation of the respiratory control ratio (RCR) (State 3/State 4 oxygen consumption) as an indicator of the degree of coupling and metabolic activity of the mitochondrial preparations.

Determination of mitochondrial protein yield

In order to determine mitochondrial yield, we first determined the total protein concentration in each mitochondrial extract by the Bradford assay. Each concentration value was multiplied by the total volume of each mitochondrial suspension. This product was divided by the skeletal muscle weight used each time to obtain the respective mitochondrial extract. Mitochondrial yield was expressed as total mitochondrial content per gram of skeletal muscle tissue.

Microarray Analysis

Details regarding sample preparation and array hybridization are described elsewhere [80] (see also Supporting File S1). Briefly, total RNA was isolated from gastrocnemius muscle using TRIZOL (Invitrogen, Carlsbad, CA, USA) and 5 individual samples from each group were used for the DNA microarray experiments. DNA chips were hybridized with synthesized biotinlabeled cRNA and scanned with a GeneArray Scanner (Affymetrix, Santa Clara, CA, USA). We performed Parametric Analysis of Gene Set Enrichment (PAGE) [23] to identify classes of genes that were differentially expressed as a result of mtDNA mutations. Genes were annotated with functional data from the Gene Ontology (GO) consortium (http://www.geneontology.org). We considered GO terms that were annotated at Level 3 or greater and were represented by at least 10 but not more than 1000 genes. A GO term was considered to be significantly changed by treatment if the p-value for both the PAGE and a False Discovery Rate (FDR) analysis was <0.01. We also calculated Z ratios for each gene set, which serve as a normalization factor [81].

Quantitative RT-PCR

Detailed protocols for quantitative RT-PCR analysis have been described [82]. The gastrocnemius muscles were dissected, frozen in liquid N2, and stored at -80° C. Total RNA was extracted from the frozen tissues using the TRIZOL reagent. Detection of mRNA was carried out with the TaqMan EZ RT-PCR kit using an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). β -Actin was used as an internal standard. Oligonucleotide primers and MGB fluorescent probes (TaqMan Gene Expression Assays) were purchased from Applied Biosystems. Samples were run in duplicate.

Oxidative Damage to mtDNA

Mitochondrial DNA oxidation was measured according to Sanz et al. [83], with modification. Briefly, mitochondrial DNA, free of nDNA, were isolated by the method of Latorre et al. [84], adapted to mammals [85]. After isolation mtDNA was completely dissolved in 85 μ L water containing 30 μ M deferoxamine mesylate (Sigma Aldrich, St. Louis, MO, USA), DNA was digested with 4 U of Nuclease P1 (dissolved in 300 mM sodium acetate, 0.2 mM ZnCl₂, pH 5.3), and 5 U of alkaline phosphatase during 60 min at 50°C. After filtering, samples were put into an autosampler vial at 4°C for HPLC-EC-UV analysis. 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo) and 2'-deoxyguanosine (dGuo) were measured by HPLC with online electrochemical and ultraviolet detection respectively. For analysis, the nucleoside mixture was injected into two Delta-Pak (150×3.9 mm id, 5 μ m) C-18 reversed-phase columns (Waters, Milford, MA, USA). 8-oxodGuo was detected with an electrochemical detector (Coulochem III, ESA Inc, Chelmsford, MA, USA) with a PEEK filter protected 5011A analytical cell (ESA, 5 nA; screen electrode: +205 mV; analytical electrode: +275), and dG was measured with a Spectra SYSTEM UV1000 detector (Thermo Electron Corp., San Jose, CA, USA) set at 290 nm. Chromatograms were recorded using EZChrome Elite (Scientific Software INC., Pleasanton, CA, USA). Calibration curves for dGuo and 8-oxodGuo were constructed by injection of each standard 3-4 times. The HPLC buffer consisted of 9% v/v methanol and 50 mM sodium acetate, set to pH 5.3, with acetic acid, then filtered through a CN 0.2 μ m filter from Nalgene Nunc (Rochester, NY, USA).

Blue native polyacrylamide gel electrophoresis (BN-PAGE) analysis for determination of content and enzymatic activity of respiratory complexes

For determination of the content of the ETC complexes, we followed the protocol as described by Schagger *et al.* with some modification [86]. Skeletal muscle was homogenized in buffer 1 containing 20 mM MOPS, 440 mM sucrose, 1 mM EDTA and 0.5 mM PMSF, pH 7.2 at 4°C. The homogenates were centrifuged at 20,000 x g for 20 min. The pellet was resuspended in 80 μ l of buffer containing 1 M aminocaproic acid, 50 mM Bistris and 0.5 mM PMSF, pH 7.0. The membranes were then solubilized by the addition of 30 μ l n-dodecylmaltoside (10%, prepared fresh), followed by ultracentrifugation for 25 min at 100,000 x g. The supernatant, containing all the solubilized mitochondrial membrane proteins was used for the BN-PAGE.

7 μ l of 5% w/v coomassie brilliant blue G-250 in aminocaproic acid (1 M) were added to 100 μ l of supernatant and samples were loaded to a gel. For electrophoresis, a 3-12% gradient gel with 4% of stacker was used. The anode buffer was comprised of 50 mM Bis-Tris, pH 7.0. The cathode buffer was comprised of 50 mM tricine, 15 mM Bis tris, and coomassie brilliant blue G-250 (0.02% w/v), pH 7.0. Samples were electrophoresed at 90 V for 20 min, and thereafter at 170 V for 2 h, at 4°C. Immediately after electrophoresis gels were incubated in coomassie brilliant blue G-250 solution (0.1% coomassie in 10% acetic acid and 40% methanol) for 1 h, followed by incubation in de-staining solution (10% acetic acid, 40% methanol) for 2 h. After de-staining, gels were photographed and analyzed using the Alpha Innotech FluorChem SP imaging system (Alpha Innotech, Santa Clara, CA, USA). Densitometry values were normalized to total protein loaded per well, measured by the Bradford assay [87]. For determination of enzymatic activity, enzymatic colorimetric reactions were performed on the BN-PAGE. Gels were incubated overnight at room temperature with the following solutions: Complex I: 2 mM Tris-HCl, pH 7.4, 0.1 mg/ml NADH, and 2.5 mg/ml NTB (nitrotetrazolium blue). Complex II: 4.5 mM EDTA, 10 mM KCN, 0.2 mM phenazine methasulfate, 84 mM succinic acid and 50 mM NTB in 1.5 mM phosphate buffer, pH 7.4. Complex IV: 5 mg 3:30-Diamidobenzidine tetrahydrochloride (DAB) dissolved in 9 ml phosphate buffer (0.05 M, pH 7.4), 1 ml catalase (20 μ g/ml), 10 mg cytochrome c, and 750 mg sucrose. Complex V: 35 mM Tris, 270 mM glycine, 14 mM MgSO₄, 0.2% Pb(NO₃)₂, and 8 mM ATP, pH 7.8. Gels were then washed in distilled water and photographed immediately. Densitometry values for activity were normalized to respective content densitometry values.

Western blots of selected mitochondrial- and nuclearencoded subunits from ETC complexes I, III, and IV

The protein content of skeletal muscle mitochondrial respiratory chain complexes was estimated using Western blot analysis. Immunodetection was performed using specific antibodies for the 39 kDa (NDUFA9) and 30 kDa (NDUFS3) subunit of complex I (1:1000 and 1:1000, respectively), 48 kDa (CORE 2) and 29 kDa (Rieske iron-sulfur protein) subunits of complex III (1:1000 and 1:1000, respectively), and COXI subunit of complex IV (1:1000) (ref. A21344, A21343, A11143, A21346 and A6403, respectively; Molecular Probes, Eugene, OR, USA). An antibody to porin (1:5000, A31855, Molecular Probes, Eugene, OR, USA) or betaactin (1:5000, AB20272, Abcam Cambridge, MA, USA), as a loading control for total mitochondrial mass or total protein content, was also used. Appropriate peroxidase-coupled secondary antibodies and chemiluminescence HRP substrate (Millipore, MA, USA) were used for primary antibody detection. Signal quantification and recording was performed with a ChemiDoc equipment (Bio-Rad Laboratories, Inc., Barcelona, Spain). Protein concentration was determined by the Bradford method [87]. Data were expressed as Arbitrary Units.

Determination of MnSOD and Catalase mRNA expression by RT-PCR

In order to extract RNA, skeletal muscles (1/10 weight/reagent volume) were homogenized in 1 mL of Tri reagent (Sigma-Aldrich, St. Louis, MO, USA) and RNA was isolated according to the manufacturer's protocol. One microgram of isolated RNA was reverse transcribed (Eppendorf RT plus PCR kit, Hamburg, Germany) using oligo-(dT) primer, as described by the manufacturer's instructions. PCR was performed on $3-\mu l$ aliquots from

each cDNA reaction, using primer sets for detecting MnSOD (5'-GGTGGCCTTGAGCGGGGACTTG-3', 5'-GGTGGGTGG-GGAGGTAGGGAGGAT-3', sense and antisense, respectively) and Catalase (5'-ATGGCCTCCGAGATCTTTTCAATG-3', 5'-GAGCGCGGTAGGGACAGTTCAC-3', sense and antisense, respectively). The sizes of the amplification products were 611 bp for MnSOD and 366 bp for Catalase. Conditions for PCR reactions were for MnSOD: 94° C for 30 sec, 58° C for 30 sec, and 72° C for 30 sec and for Catalase: 94° C for 30 sec, 57.7° C for 30 sec, and 72° C for 30 sec. PCR amplification was conducted for 29 cycles for both MnSOD and Catalase. RT-PCR products were analyzed by agarose gel electrophoresis and digital imaging of the ethidium bromide-stained gel, using the Alpha Innotech FluorChem SP imaging system (Alpha Innotech, Santa Clara, CA, USA).

Enzymatic measurement of caspase-3 and caspase-9 activities

Caspase-3 and caspase-9 activities were measured using fluorometric protease assay kits: (Caspase-3/CPP32, Caspase-9/ Mch6, Biovision, Mountain View, CA, USA) according to manufacturer's instructions. Briefly, the assays are based on detection of cleavage of the substrate DEVD-AFC (AFC: 7-amino-4-trifluoromethyl coumarin) by caspase-3, and LEHD-AFC (AFC: 7-amino-4-trifluoromethyl Coumarin) by caspase-9. DEVD-AFC and LEHD-AFC emit blue light ($\lambda_{max} = 400$ nm); upon cleavage of the respective substrate by caspase-3 or caspase-9, free AFC emits a yellow-green fluorescence ($\lambda_{max} = 505$ nm), which can be quantified using a fluorescence units per mg of cytosolic protein.

Determination of cytosolic mono- and oligonucleosomes

Apoptotic DNA fragmentation was quantified in skeletal muscle by measuring the amount of cytosolic mono- and oligonucleosomes using a Cell Death detection ELISA (Roche, Germany). Briefly, wells were coated with a monoclonal anti-histone antibody. Nucleosomes in the sample bound to the antibody followed by the addition of anti-DNA-peroxidase, which reacted with the DNA associated with the histones. The amount of peroxidase retained in the immunocomplex was determined spectrophotometrically with ABTS (2.2'-azino-di-[3-ethylbenzthiazoline sulfonate]) as a substrate. Results were expressed as arbitrary OD units normalized to mg of cytosolic protein.

DNA laddering

To enable detection of nucleosomal ladders in apoptotic cells, the DNA ladder assay was performed. Skeletal muscle was homogenized in 1 mL DNAzol (Molecular Research Center Inc., Cincinnati, OH, USA). Proteinase K (Qiagen, Valencia, CA, USA) was added to the homogenates, which, after a 3 h incubation period, were centrifuged $(10,000 \times g \text{ for } 10 \text{ min at})$ 4°C) and the supernatants were precipitated and washed with 100% and 75% ethanol, respectively. After digestion with RNase A, DNA samples were subjected to a DNA ladder-specific ligationmediated PCR, following the manufacturer's protocol (Maxim Biotech, San Francisco, CA, USA). Briefly, isolated DNA is subjected to an overnight ligation reaction using de-phosphorylated adaptors (12-mer: 5'-AGTCGACACGTG-3', 27-mer: 5'-GACGTCGACGTCGTACACGTGTCGACT-3') that are ligated to the ends of DNA fragments generated during apoptosis, using T4 DNA ligase. When the mixture is heated to 55°C, the 12mer is released. Next, the 5' protruding ends of the molecules are filled by Taq polymerase. The 27-mer then serves as a primer for

PCR in which the fragments with adaptors on both ends are amplified. Conditions for PCR reactions were 72°C for 10 min, 94°C for 1 min, followed by 30 cycles of 94°C for 1 min and 70°C for 2 min. PCR products were electrophoresed through 1% agarose gels containing 0.5 μ g/mL ethidium bromide at 80 V for 1 h, and were examined under UV light for the presence of apoptosis-specific nucleosomal ladders.

Statistical Analyses

All results are expressed as means \pm SEM and the means were compared by independent t-tests. Statistical analyses were carried out using the Graph-Pad Prism 4.0 statistical analysis program (San Diego, CA). Statistical significance was set to p<0.05.

Supporting Information

 Table S1
 Gene expression changes in gastrocnemius muscle of 13-month-old D257A mice compared to wild type mice.

Found at: doi:10.1371/journal.pone.0011468.s001 (0.03 MB XLS)

Figure S1 No differences between WT and D257A skeletal muscle in mitochondrial respiration at 3-mo of age. We determined the effects of mtDNA mutations on O2 consumption of skeletal muscle mitochondria obtained from 3-mo old (n = 8 per group) WT and D257A mice. The respiratory control ratio (RCR), an index of mitochondrial coupling and metabolic efficiency of mitochondrial preparations, was calculated by dividing state 3 by state 4 respiration values. No statistically significant differences were detected. Error bars represent SEM.

Found at: doi:10.1371/journal.pone.0011468.s002 (0.15 MB TIF)

Figure S2 No differences in total basal and site-specific reactive oxygen species production at 3-mo of age. Skeletal muscle mitochondria were obtained from 3-mo old (n=8 per group) WT and D257A mice. We evaluated H2O2 production at complex I in mitochondria supplemented with pyruvate/malate (panel A) because it represents total basal mitochondrial ROS generation. We also used inhibitors of the ETC in order to study maximum rates of H2O2 production from complexes I and III because they represent the main sites of ROS generation within

References

- 1. Marcell TJ (2003) Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 58: M911–916.
- Roubenoff R (2000) Sarcopenia and its implications for the elderly. Eur J Clin Nutr 54 Suppl 3: S40–47.
- Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R (2004) Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 159: 413–421.
- Alexeyev MF, Ledoux SP, Wilson GL (2004) Mitochondrial DNA and aging. Clin Sci (Lond) 107: 355–364.
- Hiona A, Leeuwenburgh C (2008) The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol 43: 24–33.
- Barja G, Herrero A (2000) Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. Faseb J 14: 312–318.
- Herrero A, Barja G (1999) 8-oxo-deoxyguanosine levels in heart and brain mitochondrial and nuclear DNA of two mammals and three birds in relation to their different rates of aging. Aging (Milano) 11: 294–300.
- Bohr VA, Dianov GL (1999) Oxidative DNA damage processing in nuclear and mitochondrial DNA. Biochimie 81: 155–160.
- Larsen NB, Rasmussen M, Rasmussen LJ (2005) Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion 5: 89–108.
- Wilson DM, 3rd, Bohr VA (2007) The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 6: 544–559.
- Harman D (1972) Free radical theory of aging: dietary implications. Am J Clin Nutr 25: 839–843.
- Harman D (1972) The biologic clock: the mitochondria? J Am Geriatr Soc 20: 145–147.

the mitochondria. For measuring the maximal rate of ROS production at complex I (panel B), we added rotenone to pyruvate/malate-supplemented mitochondria. For measurements of the maximum rate of ROS generation at complex III (panel E), we added antimycin A plus rotenone to succinate-supplemented mitochondria. We also used mitochondria supplemented with succinate alone (i.e., in the absence of any respiratory inhibitors) in order to study complex III ROS production under near physiological conditions (panel C). In addition, some of the assays with succinate as substrate were performed in the presence of rotenone (panel D), in order to avoid the backwards flow of electrons through Complex I. Free radical leak (FRL%), an index of mitochondrial efficiency (panel F), was calculated by dividing the H2O2 production value by twice the state 4 respiration value and the result was multiplied by 100 to give a final percentage value. No statistically significant differences were detected. Error bars represent SEM.

Found at: doi:10.1371/journal.pone.0011468.s003 (0.44 MB TIF)

Supporting File S1 Minimum information about a microarray experiment check list. Supplemental description of gene expression analysis of skeletal muscle from wild type and mitochondrial mutator mice.

Found at: doi:10.1371/journal.pone.0011468.s004 (0.03 MB DOC)

Acknowledgments

We thank Rizwan Kalani, Evelyn Kouwenhoven, Alba Naudi and Emanuele Marzetti for excellent technical assistance. We thank Dr. Yuichi Goto from the Department of Molecular Genetics at the National Institute of Neuroscience (Tokyo, Japan) for support in type 1 fiber diameter measurements. We also thank Miguel Garcia for expert advice.

Author Contributions

Conceived and designed the experiments: AH AS GCK S. Someya S. Servais MT TAP CL. Performed the experiments: AH AS RP AYS TH S. Someya TM CN AKSA MPO. Analyzed the data: AH AS GCK RP AYS TH S. Someya TM CN AKSA JLB MPO. Contributed reagents/materials/analysis tools: AH AS GCK RP AYS TH S. Someya TM CN AKSA S. Servais MPO MT TAP. Wrote the paper: AH AS GCK S. Someya TAP CL.

- Fleming JE, Miquel J, Cottrell SF, Yengoyan LS, Economos AC (1982) Is cell aging caused by respiration-dependent injury to the mitochondrial genome? Gerontology 28: 44–53.
- Wanagat J, Cao Z, Pathare P, Aiken JM (2001) Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. Faseb J 15: 322–332.
- Khaidakov M, Heflich RH, Manjanatha MG, Myers MB, Aidoo A (2003) Accumulation of point mutations in mitochondrial DNA of aging mice. Mutat Res 526: 1–7.
- Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC (1992) Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 275: 169–180.
- Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, et al. (1992) Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 2: 324–329.
- Lee CM, Chung SS, Kaczkowski JM, Weindruch R, Aiken JM (1993) Multiple mitochondrial DNA deletions associated with age in skeletal muscle of rhesus monkeys. J Gerontol 48: B201–205.
- Wang Y, Michikawa Y, Mallidis C, Bai Y, Woodhouse L, et al. (2001) Musclespecific mutations accumulate with aging in critical human mtDNA control sites for replication. Proc Natl Acad Sci U S A 98: 4022–4027.
- Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, et al. (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481–484.
- Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, et al. (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417–423.

- Troyer DL, Oyster RA, Leipold HW (1990) A rapid and reliable sequential staining method for bovine muscle. Anat Histol Embryol 19: 154–157.
- Kim SY, Volsky DJ (2005) PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 6: 144.
- Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, et al. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727–730.
- Edwards MG, Anderson RM, Yuan M, Kendziorski CM, Weindruch R, et al. (2007) Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program. BMC Genomics 8: 80.
- Edgar D, Shabalina I, Camara Y, Wredenberg A, Calvaruso MA, et al. (2009) Random point mutations with major effects on protein-coding genes are the driving force behind premature aging in mtDNA mutator mice. Cell Metab 10: 131–138.
- Cortopassi GA, Arnheim N (1990) Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 18: 6927–6933.
- Linnane AW, Baumer A, Maxwell RJ, Preston H, Zhang CF, et al. (1990) Mitochondrial gene mutation: the ageing process and degenerative diseases. Biochem Int 22: 1067–1076.
- Melov S, Hertz GZ, Stormo GD, Johnson TE (1994) Detection of deletions in the mitochondrial genome of Caenorhabditis elegans. Nucleic Acids Res 22: 1075–1078.
- Chung SS, Weindruch R, Schwarze SR, McKenzie DI, Aiken JM (1994) Multiple age-associated mitochondrial DNA deletions in skeletal muscle of mice. Aging (Milano) 6: 193–200.
- Bua E, Johnson J, Herbst A, Delong B, McKenzie D, et al. (2006) Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 79: 469–480.
- Cao Z, Wanagat J, McKiernan SH, Aiken JM (2001) Mitochondrial DNA deletion mutations are concomitant with ragged red regions of individual, aged muscle fibers: analysis by laser-capture microdissection. Nucleic Acids Res 29: 4502–4508.
- Fayet G, Jansson M, Sternberg D, Moslemi AR, Blondy P, et al. (2002) Ageing muscle: clonal expansions of mitochondrial DNA point mutations and deletions cause focal impairment of mitochondrial function. Neuromuscul Disord 12: 484–493.
- McKiernan SH, Bua E, McGorray J, Aiken J (2004) Early-onset calorie restriction conserves fiber number in aging rat skeletal muscle. Faseb J 18: 580–581.
- Proctor DN, Sinning WE, Walro JM, Sieck GC, Lemon PW (1995) Oxidative capacity of human muscle fiber types: effects of age and training status. J Appl Physiol 78: 2033–2038.
- Short KR, Bigclow ML, Kahl J, Singh R, Coenen-Schimke J, et al. (2005) Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 102: 5618–5623.
- Dubessay P, Garreau-Balandier I, Jarrousse AS, Fleuriet A, Sion B, et al. (2007) Aging impact on biochemical activities and gene expression of Drosophila melanogaster mitochondria. Biochimie.
- Ferguson M, Mockett RJ, Shen Y, Orr WC, Sohal RS (2005) Age-associated decline in mitochondrial respiration and electron transport in Drosophila melanogaster. Biochem J 390: 501–511.
- Marcinek DJ, Schenkman KA, Ciesielski WA, Lee D, Conley KE (2005) Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle. J Physiol 569: 467–473.
- Mansouri A, Muller FL, Liu Y, Ng R, Faulkner J, et al. (2006) Alterations in mitochondrial function, hydrogen peroxide release and oxidative damage in mouse hind-limb skeletal muscle during aging. Mech Ageing Dev 127: 298–306.
- Drew B, Phaneuf S, Dirks A, Selman C, Gredilla R, et al. (2003) Effects of aging and caloric restriction on mitochondrial energy production in gastrocnemius muscle and heart. Am J Physiol Regul Integr Comp Physiol 284: R474–480.
- Trifunovic A, Hansson A, Wredenberg A, Rovio AT, Dufour E, et al. (2005) Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci U S A 102: 17993–17998.
- Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, et al. (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 99: 1870–1875.
- Hagen TM, Yowe DL, Bartholomew JC, Wehr CM, Do KL, et al. (1997) Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci U S A 94: 3064–3069.
- Pieri C, Recchioni R, Moroni F (1993) Age-dependent modifications of mitochondrial trans-membrane potential and mass in rat splenic lymphocytes during proliferation. Mech Ageing Dev 70: 201–212.
- Miyoshi N, Oubrahim H, Chock PB, Stadtman ER (2006) Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Natl Acad Sci U S A 103: 1727–1731.
- Harper ME, Monemdjou S, Ramsey JJ, Weindruch R (1998) Age-related increase in mitochondrial proton leak and decrease in ATP turnover reactions in mouse hepatocytes. Am J Physiol 275: E197–206.
- Gottlieb E, Armour SM, Harris MH, Thompson CB (2003) Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 10: 709–717.
- Dirks A, Leeuwenburgh C (2002) Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 282: R519–527.

- Dirks AJ, Leeuwenburgh C (2004) Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, Xlinked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med 36: 27–39.
- Ott M, Gogvadze V, Orrenius S, Zhivotovsky B (2007) Mitochondria, oxidative stress and cell death. Apoptosis 12: 913–922.
- Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 47: 143–183.
- Izyumov DS, Avetisyan AV, Pletjushkina OY, Sakharov DV, Wirtz KW, et al. (2004) "Wages of fear": transient threefold decrease in intracellular ATP level imposes apoptosis. Biochim Biophys Acta 1658: 141–147.
- Herbst A, Pak JW, McKenzie D, Bua E, Bassiouni M, et al. (2007) Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss. J Gerontol A Biol Sci Med Sci 62: 235–245.
- Bua EA, McKiernan SH, Wanagat J, McKenzie D, Aiken JM (2002) Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol 92: 2617–2624.
- McKenzie D, Bua E, McKiernan S, Cao Z, Aiken JM (2002) Mitochondrial DNA deletion mutations: a causal role in sarcopenia. Eur J Biochem 269: 2010–2015.
- Chabi B, de Camaret BM, Chevrollier A, Boisgard S, Stepien G (2005) Random mtDNA deletions and functional consequence in aged human skeletal muscle. Biochem Biophys Res Commun 332: 542–549.
- Desai VG, Weindruch R, Hart RW, Feuers RJ (1996) Influences of age and dietary restriction on gastrocnemius electron transport system activities in mice. Arch Biochem Biophys 333: 145–151.
- Alemi M, Prigione A, Wong A, Schoenfeld R, DiMauro S, et al. (2007) Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript. Free Radic Biol Med 42: 32–43.
- Beyer RE, Starnes JW, Edington DW, Lipton RJ, Compton RT, 3rd, et al. (1984) Exercise-induced reversal of age-related declines of oxidative reactions, mitochondrial yield, and flavins in skeletal muscle of the rat. Mech Ageing Dev 24: 309–323.
- Kerner J, Turkaly PJ, Minkler PE, Hoppel CL (2001) Aging skeletal muscle mitochondria in the rat: decreased uncoupling protein-3 content. Am J Physiol Endocrinol Metab 281: E1054–1062.
- Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, et al. (2008) Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell 7: 2–12.
- Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298–300.
- 64. Geromel V, Kadhom N, Cebalos-Picot I, Ouari O, Polidori A, et al. (2001) Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene of the mitochondrial DNA. Hum Mol Genet 10: 1221–1228.
- Pitkanen S, Robinson BH (1996) Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 98: 345–351.
- Mott JL, Zhang D, Stevens M, Chang S, Denniger G, et al. (2001) Oxidative stress is not an obligate mediator of disease provoked by mitochondrial DNA mutations. Mutat Res 474: 35–45.
- Tahara EB, Navarete FD, Kowaltowski AJ (2009) Tissue-, substrate-, and sitespecific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med 46: 1283–1297.
- Boveris A, Chance B (1973) The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134: 707–716.
- Korshunov SS, Skulachev VP, Starkov AA (1997) High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 416: 15–18.
- Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, et al. (2007) Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39: 540–543.
- Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, et al. (2008) DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40: 392–394.
- Bandy B, Davison AJ (1990) Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med 8: 523–539.
- Katayama M, Tanaka M, Yamamoto H, Ohbayashi T, Nimura Y, et al. (1991) Deleted mitochondrial DNA in the skeletal muscle of aged individuals. Biochem Int 25: 47–56.
- Muller-Hocker J, Seibel P, Schneiderbanger K, Kadenbach B (1993) Different in situ hybridization patterns of mitochondrial DNA in cytochrome c oxidasedeficient extraocular muscle fibres in the elderly. Virchows Arch A Pathol Anat Histopathol 422: 7–15.
- Brierley EJ, Johnson MA, Lightowlers RN, James OF, Turnbull DM (1998) Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol 43: 217–223.
- Sanz A, Hiona A, Kujoth GC, Seo AY, Hofer T, et al. (2007) Evaluation of sex differences on mitochondrial bioenergetics and apoptosis in mice. Exp Gerontol 42: 173–182.
- Barja G (2002) The quantitative measurement of H2O2 generation in isolated mitochondria. J Bioenerg Biomembr 34: 227–233.

- Drew B, Leeuwenburgh C (2003) Method for measuring ATP production in isolated mitochondria: ATP production in brain and liver mitochondria of Fischer-344 rats with age and caloric restriction. Am J Physiol Regul Integr Comp Physiol 285: R1259–1267.
- Scaduto RC, Jr., Grotyohann LW (1999) Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76: 469–477.
- Lee CK, Klopp RG, Weindruch R, Prolla TA (1999) Gene expression profile of aging and its retardation by caloric restriction. Science 285: 1390–1393.
- Cheadle C, Cho-Chung YS, Becker KG, Vawter MP (2003) Application of zscore transformation to Affymetrix data. Appl Bioinformatics 2: 209–217.
- Someya S, Yamasoba T, Prolla TA, Tanokura M (2007) Genes encoding mitochondrial respiratory chain components are profoundly down-regulated with aging in the cochlea of DBA/2J mice. Brain Res 1182: 26–33.
- Sanz A, Gredilla R, Pamplona R, Portero-Otin M, Vara E, et al. (2005) Effect of insulin and growth hormone on rat heart and liver oxidative stress in control and caloric restricted animals. Biogerontology 6: 15–26.
- Latorre A, Moya A, Ayala FJ (1986) Evolution of mitochondrial DNA in Drosophila subobscura. Proc Natl Acad Sci U S A 83: 8649–8653.
- de la Asuncion JG, Millan A, Pla R, Bruseghini L, Esteras A, et al. (1996) Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. FASEB J 10: 333–338.
- Schagger H, von Jagow G (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 199: 223–231.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.